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 Malaria is a mosquito-harbored infectious disease causing approximately half 
a million deaths every year around the world. Out of the five Plasmodium species 
that infect humans, P. falciparum is the deadliest. Despite the relative success in 
decreasing malaria-related deaths through various efforts, emergence of parasite 
resistance against antimalarials remains a major challenge. This is mainly because 
the parasite develops resistance before new effective drugs can become available. In 
addition, there is no approved vaccine for malaria that will prevent the infection in 
most groups affected. The protection offered by the malaria vaccine candidate, 
RTS,S, currently on phase III clinical trials,  is less than 40% in children when used 
along with bed nets and other malaria prevention recommendations. Additional 
vaccine candidates are needed to provide better protection against malaria. The 
characterization of molecular targets allows the development of inhibitors against 
the parasite via rational design, helping to advance the development of vaccine and 
treatment.  
 Subtilisin-like protease 2 (SUB2) is the only Plasmodium subtilisin playing a 
direct role during invasion of the red blood cell (RBC), a critical step in malaria 
parasite development during the asexual, symptom-causing stages. SUB2 merozoite 
surface sheddase (MeSh) activity is essential for parasite survival and RBC invasion. 
A SUB2-specic inhibitor will lead to impairment of invasion. Additionally, SUB2 is 
secreted onto the surface of the parasite to access its substrates, staying exposed to 
the antibodies in the blood, making it a merozoite surface antigen itself and a 
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candidate for antibody-mediated inhibition. This makes SUB2 both a potential drug 
target and a vaccine candidate.  
 At the present, our understanding of SUB2 biochemistry and biophysical 
properties is limited and now studies have tested this subtilisin as a vaccine 
candidate. In this dissertation, we show that antibody-mediated inhibition results in 
decreased parasite infection in a proof-of-principle experiment with mice. We have 
also attempted to characterize the two SUB2 peptides utilized in immunization 
experiments by using a self-assembling protein nanoparticle on a different, but 
related, experiment using a mouse model of malaria. Finally, we develop an 
expression system for active SUB2 as well as a SUB2-specific protease assay with 
native SUB2 substrates. 
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 Malaria is an infectious disease caused by obligate intracellular parasites of 
the genus Plasmodium.  Five Plasmodium species have been identified to infect 
humans and P. falciparum is known to be the deadliest[1]. Given the appropriate 
resources and knowledge, malaria is a preventable and treatable disease.  However, 
at least half a million deaths are attributed to malaria worldwide every year [1] .  
 In theory, successful control measurements and treatment of an infectious 
disease can be achieved by studying the pathogen responsible of it. Since the late 
1880s the causative agent of malaria was known to be a protozoan organism and its 
mode of transmission was known by the early 1900s [2]. By understanding the 
causative agent of a disease and its mode of transmission, it is possible to start 
working on a strategy to deal with this illness. As an example, a mosquito can be 
killed with insecticides (e.g. DDT) and the vector populations can effectively be 
reduced when the water sources where they develop are removed [3]. Likewise, the 
more we study the pathogen itself, the more information we gather in order to 
target specific mechanisms for its intervention. At the present, we can take 
advantage of new methods and technologies to design molecules against the 
parasite upon the characterization of chosen molecular targets [4, 5]. Similar 
approaches can also be employed to characterize antigens for the development of 
new vaccines for the prevention of malaria [6]. 
 Numerous factors contribute to the difficulty in controlling malaria in some 
regions. Some of these contributing factors are [1]: the emergence of drug-resistant 
 3 
strains of the parasite, insecticide resistance of the mosquito vectors, environmental 
conditions that favor the spread of mosquitoes, quality and availability of 
antimalarial drugs, the political and economical stability of the affected regions, 
resources, cultural and religious beliefs, among others. In this case, to control 
malaria in the regions where it is still endemic, it is critical to have all the necessary 
components.   The ultimate goal is to eradicate malaria worldwide, as it was possible 
to accomplish in some regions of the world several decades ago [7, 8]. 
 A crucial part of this plan is to have effective antimalarial treatment available. 
One of the major challenges that we face in our fight against malaria is that the 
parasite quickly develops resistance against malaria pharmacotherapy. In the late 
1950s, chloroquine resistance was already discovered. More recently, at the 
beginning of 2015, artemisinin resistance was reported in the Myanmar-Indian 
border. Resistance to this frontline treatment against malaria was also reported in 
Cambodia, Laos, Thailand, Vietnam and Myanmar. As a result, artemisinin-based 
combination therapies can rapidly become less effective in the regions where it is 
needed the most. This scenario is particularly alarming, as parasite resistance can 
potentially spread in sub-Saharan Africa, where most of P. falciparum malaria 
deaths are reported [1]. 
 
Malaria prevention and other control measurements 
 To compensate for parasite resistance to existing antimalarials, new 
compounds have been developed [1].  Still, not all compounds are recommended for 
general use unless there is strong evidence of effectiveness and safety. For that 
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reason, the more compounds we have available, the better the chances we have to 
find those that are effective and safe to use. We will also continue learning about 
which classes of compounds act better on the parasite and identify those that are 
safer for humans.  Moreover, taking into consideration that malaria is treated 
differently depending on the severity of the disease (e.g. uncomplicated vs. severe 
malaria), the individual affected (e.g. children, pregnant women, travelers with no 
immunity) and the malaria species that is being treated for, we definitely need to 
have in hand a variety of compounds with different mechanisms of action. This will 
allow us to treat every malaria case properly, reducing the amounts of deaths.  
Appropriate use of antimalarials could impact the development of drug resistance in 
the parasite by reducing the occurrence of these resistant strains. As a consequence, 
effective drugs will remain functional for a longer period of time.  Again, this 
highlights the importance to continue developing novel compounds against malaria. 
 Rational drug design [9] promises to aid in hastening the development of 
effective and safe antimalarials. This methodology consists in developing 
compounds for a known and specific molecular target, ideally, one that has a critical 
function in an indispensable biological process of the parasite. This approach 
utilizes structural information in combination with biochemical, computational and 
biophysical methods to identify and develop new molecules.  In this way, 
compounds whose molecular targets are known and have been previously 
characterized and extensively studied, in general, can be developed. 
 Vaccines are among the vital components in the fight against malaria and 
they can also be developed based on a specific target [1]. RTS,S/AS01 [10] is 
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currently in Phase III trials in seven countries in sub-Saharan Africa. This is one of 
the first antimalarial vaccines that have been developed, and it has been evaluated 
as a component of other preventive measurements such as, artemisinin-based 
treatment, and insecticide nets. 
  
 
The malaria parasite 
 
 Malaria is an infectious disease caused by unicellular eukaryotic organisms of 
the genus Plasmodium. These obligate intracellular parasites belong to the phylum 
Apicomplexa. This group is characterized by containing a plastid-like organelle: the 
apicoplast and a complex apical structure utilized in host cell invasion. Over 100 
species of Plasmodium parasites have been identified. They are known to infect 
several vertebrate species including reptiles, birds and mammals. Identifying the 
species of malaria that affect different vertebrates is important for species 
conservation, agriculture, ecology, economy and medicine.  It is known that malaria 
infection in humans causes more than half a million deaths every year[1]. 
 Five Plasmodium species are known to infect humans: P. falciparum, P. vivax, 
P. ovale (two species) and P. malariae [1].  Non-human primate malaria species can 
also infect humans, which is the case for P. knowlesi. All human and non-human 
Plasmodium species require a mosquito and a vertebrate host to complete all the 
stages of their life cycle (Figure 1.1). For the purpose of our studies, we are mainly 
interested in P. falciparum because it is the human malaria species that causes most 
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deaths worldwide [1]  . We also study P. berghei, a mouse malaria species, in order 
to perform malaria infection experiments in vivo with a model vertebrate[11]. 
 
Sexual development: mosquito stages 
 The malaria parasite undergoes sexual development in the mosquito host 
[12]. For this reason, the mosquito is considered its definitive host. Out of the 
thousands mosquito groups, only Anopheles mosquitoes are known to transmit 
malaria. Transmission to the human host occurs when an infected mosquito delivers 
saliva with sporozoites during a blood meal.  
 A mosquito becomes infected after feeding on an infected human that has 
early sexual stages of the parasite circulating in the blood [13, 14].  A few male and 
female gametocytes are ingested, mixed in the blood meal. Once inside the 
mosquito’s gut, these mature into gametes and fertilization occurs, leading to the 
development of a motile zygote: the ookinete [13].  Once an ookinete is formed, it 
has to invade the epithelial cells in the mosquito to move across the midgut until it 
has access to the basal lamina, where it stays immobilized as an oocyst [12].  At this 
point in the life cycle, the number of parasites present in the host is greatly reduced. 
Out of the billions of parasites circulating in the human blood, less than 10 ookinetes 
usually develop into oocysts in the wild.  For this reason, the ookinete is considered 
a bottleneck [15, 16] point during sexual development, which makes this stage an 
attractive target for small molecule or antibody-mediated intervention in the 
mosquito.  
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 Once the oocyst develops, the parasite undergoes multiple replications to 
increase in numbers and it specializes into an immature form of the infectious stage 
to humans: the sporozoite. Sporozoites are then released into the mosquito’s 
hemocoel and “circulatory system” so they can migrate and invade the salivary 
glands to completely mature and become infectious to humans [17]. Once in the 
salivary glands, the parasites are ready to be transmitted during a bite. This is the 
stage that is targeted by the current malaria RTS,S vaccine [18] after they enter the 
human. Priming the human immune system to recognize and interfere with the 
sporozoites before they reach the liver and continue their life cycle is a valid vaccine 
strategy. 
 Sexual development is important for recombination of genetic material, 
which results in species stability. By this mean, the parasite also acquires and 
maintains genetic changes that confer resistance to drugs. Targeting mosquito 
stages for transmission control strategies [19] can prevent the spread of new drug-
resistant strains, besides the fact that it will reduce the number of cases of malaria. 
Bottleneck stages are an attractive target for chemotherapeutic intervention 
because the number of parasites is already reduced.  
 
Liver stage 
 After being deposited in the human skin through a mosquito bite, the 
sporozoites have to find their way to the liver in order to continue their life cycle 
[20].  The parasites are delivered to the liver via the blood stream after they find the 
capillaries in the skin. Once in the liver, the parasite transverses and invades the 
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hepatocytes until they start to transform and develop [20]. During development in 
the liver [21], the parasite undergoes several rounds of replication to increase in 
numbers and transforms into a merosome [20], containing merozoites. These 
merozoites are equipped with molecular components that allow the parasite to 
invade the circulating red blood cells and develop within them [22].  Fully 
developed merozoites are released from the liver into the blood stream, where they 
have access to another target host cell: the erythrocyte [22].  
 In the liver, the parasite is refuged from the immune system within the 
hepatocytes [16], leading to no signs of infection. Two human malaria species (P. 
vivax and P. ovale) can remain dormant at this stage [23, 24] for several weeks, 
without being released into the blood. The Plasmodium liver stage also represents a 
bottleneck in the life cycle since the number of parasites is also reduced from almost 
a hundred sporozoites that are injected by the mosquito, to a few merosomes that 
develop finally in the hepatocytes. The liver stage is a target for preventing malaria 
infection in the blood once the parasite is transmitted to the human host.  
 
Asexual cycle: blood stages in the human host 
  For the necessary stages, this obligate intracellular parasite has the 
molecular components for recognizing, invading and developing within a host cell 
[25, 26].  The merozoite is a highly specialized polar cell that contains all the 
components necessary for red blood cell invasion at its surface and inside 
specialized organelles that are discharged through the apical end of the cell during 
the process of invasion [27]. But first, the free merozoite has to encounter a red 
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blood cell and become attached to it. Then RBC invasion takes place until the 
parasite has completely entered the cell without breaking the RBC membrane. As a 
result of the invasion process, the parasite ends up surrounded by the outside of the 
erythrocyte membrane previously exposed to the extracellular space, which is 
subsequently modified by the parasite during the development [22]. 
 There are four forms of the parasite during the RBC cycle [28]: the merozoite, 
the ring, the trophozoite and the schizont. Of these, only a merozoite is an 
extracellular form, for a short period of time between egress from the RBC and RBC 
invasion. The other forms consist of other developmental stages within the RBC.  
The ring stage develops after the invasion of the RBC is completed.  At this stage, the 
parasite is transformed and begins to become metabolically active.  After this, the 
trophozoite starts to develop, increases in size and becomes highly metabolically 
active. During this stage, the parasite starts to feed on the very abundant 
hemoglobin protein in the RBC [29, 30]. Metabolic activity of the parasite is greatly 
increased such that several distinct cellular processes are taking place. The host cell 
is being modified by the parasite, P. falciparum, and the surface of the erythrocyte is 
modified so that this host cell can attach to the endothelium in the circulatory 
system and stay sequestered during the rest of the parasite development [31-33]. 
Thus, only early stages of the parasite circulate in the blood.  
 Later asexual stages, however, stay circulating in the blood for the other 
human malaria species. The stage referred to as the schizont begins with an increase 
of genomic material due to genomic DNA replication. After the entire genomic 
content of the parasite is replicated several times, the daughter cells begin to form 
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and the formation of new merozoites takes place. These new merozoites will then 
egress from this infected erythrocyte in order to invade uninfected RBCs that are 
circulating in the blood [22]. Then, the parasite will start development within the 
RBC once again, perpetuating this asexual cycle. These intraerythrocytic stages will 
continue to develop until the parasite is eliminated by the host’s immune system or 
until it kills the host.  P. falciparum is the human malaria species that is responsible 
for more deaths as a consequence of complications that develop during asexual 
stages of the parasite. 
 The parasites in the RBC are largely hidden from the human immune system 
[34]. The malaria symptoms arise only when the merozoites are free in the blood 
and can be detected by the immune system for a short period of time. During this 
window, the parasite is exposed to all the components of the human blood, including 
antibodies that can have access to the proteins at the surface of the merozoites [35-
38]. This offers an opportunity for interfering with the parasite before it infects 
another RBC. The rapid and diverse metabolic processes taking place at this stage 
make it an optimal target for antimalarial drugs. 
 
Red blood cell invasion  
 Invasion of a host cell is essential for the survival of an obligate intracellular 
parasite such as Plasmodium.  Entering a host cell guarantees a plentiful food source 
and refuge from the immune system while ensuring appropriate development 
needed to continue the life cycle [22, 26, 34, 39].  Red blood cell invasion occurs in 
highly regulated steps.  First, the parasite attaches to the surface of the erythrocyte 
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in a non-specific orientation. Presumably, this initial contact results from the 
accidental encounter of a free merozoite and a circulating RBC. This attachment is 
mediated by adhesins at the surface of the merozoite that engage receptors on the 
erythrocyte membrane [22]. Secondly, the parasite reorients itself so that the apical 
domain is facing towards the surface of the RBC. Subsequently, the proteins 
involved in the process of invasion are discharged from secretory organelles in a 
sequential manner to assure proper control of this process [22].  
 Disruption of any important step in this process would be expected to result 
in unsuccessful invasion and parasite death. For instance, surface ligand processing 
for maturation is necessary for successful invasion. Two well-studied surface 
adhesins are merozoite surface protein 1 (MSP1) [40-42] and apical membrane 
antigen 1 (AMA1) [43, 44].  These are prime targets for vaccine and drug 
development. These proteins coat the surface of the merozoite and interact with 
their receptor partners at the surface of the erythrocyte.  This attachment is 
resolved by the removal of the ectodomain of these ligands by a single cleavage 
event at a flexible juxtamembrane site performed by a sheddase [25, 45]. This 
surface sheddase, subtilisin-like protease 2, carries out the key maturation step for 
these ligands. The catalytic activity of this protease is essential for RBC invasion.  As 
with any critical step of a biological process, inhibition of SUB2 activity would 
render this host invasion step unsuccessful, stopping the life cycle of the parasite at 
this point. 
 In the case where SUB2 activity is carried out as usual, the process of 
invasion would continue uninterrupted to completion once the parasite becomes 
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completely enclosed in the RBC membrane. During this process, the outer 
membrane of the RBC forms the parasitophorous vacuole inside the now infected 
erythrocyte. This complex process of invasion is also supported by other 
components such as an actin-myosin motor, ions and other multifunctional proteins, 
providing several targets for inhibition. For the purpose of this dissertation, 
however, we will focus on SUB2, the second identified Plasmodium subtilisin-like 
protease, which has been established to perform a critical role in invasion and is 
therefore essential to parasite survival. 
 
Gametocytes in the blood: and so the life cycle continues 
 Male and female gametocytes [46] develop during the blood stages of the 
parasite [14]. These are early forms of sexual stages and only can continue their 
development within the mosquito. Micro- and macrogametes are ingested in the 
blood meal mixture when a mosquito feeds. Subsequently, these gametes will 
mature inside the mosquito’s digestive system and fuse to form the ookinete [13].  If 
there is no interference with these developmental stages, the malaria parasite will 
develop further inside the mosquito, thereby allowing the infection cycle to be 
completed. And, once again, the infectious form of Plasmodium, the sporozoites, will 
be transmitted to another human during the next blood meal. 
 
Conclusion 
 In general, the complex life cycle of the malaria parasite offers multiple 
points for intervention. The asexual cycle in the red blood cells is of special interest 
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because it results in malaria symptoms in humans. Severe malaria cases, especially 
those caused by P. falciparum, can be fatal, mostly to children and pregnant women. 
Thus, characterization of molecular targets during this stage can help to develop 
new treatment and vaccines. Other stages are also of interest for malaria prevention 
and transmission control. 
 
 
Proteases at the service of pathogens  
 
 All proteases share a common characteristic: they all catalyze a 
reaction that results in the breaking a peptide bond of a given substrate [47]. The 
biochemical environment at the active site determines the specific reaction 
mechanism, in this case, amino acid residues, metal ions, water and other small 
molecules that may be involved in the biochemistry of a specific protease [48]. As 
can be expected, there are many other factors that determine substrate specificity, 
substrate access, and the active or inactive form of the protease, among others. All of 
these factors allow controlling and specifying the impact of a protease on a given 
cellular function. In this way, proteases can perform a vast variety of roles. They 
function as activators or inhibitors of protein function,; they are involved in 
maturation of ligands and receptors, in the release signaling molecules, and have 
essential roles in cell death, in the pathogenesis of parasites and perform other vital 
functions in other organisms [49-56]. 
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Proteases as key targets for treatment of infectious diseases 
 Infectious agents often require the function of proteases for 
pathogenesis [57-59], survival and development within the host. In some cases, it is 
protease produced by the parasite itself, in other cases; the parasite uses the host’s 
proteases to carry out a function for them. An example of the latter case is the use of 
host serine proteases to cleave the influenza virus hemagglutinin (HA) to permit the 
virus to gain entry into the epithelial cells in the respiratory tract [60, 61]; targeting 
the activity of this protease would be expected (or is known to?) halt virus 
propagation. A similar strategy is used by other viruses, including Ebola virus, the 
SARS-coronavirus and the MERS-coronavirus [62-67]. Thus, the development of 
specific protease inhibitors is a promising strategy to prevent the spread of these 
viruses within the host. Still other viruses code for proteases that can be used as 
targets, one notable success story involves development of antiretroviral 
therapeutics against HIV-1 infection, which are based in part on protease inhibitors 
that target HIV-1 aspartic protease [68-71].  
 The involvement of proteases in pathogenesis is not only observed 
with human viruses but also with other disease-causing agents, such as bacteria and 
protozoan parasites. As an example, Ralstonia pickettii, causes severe bacterial 
infections to individuals with poor health and is usually acquired in hospitals [72]. A 
metalloprotease was found to contribute to the cytotoxic activity. As another 
example, Entamoeba histolytica, is a protozoan parasite that uses the action of 
secreted cysteine proteases to adhere to the host cells [73].  
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 Protease inhibitors are often used as chemotherapy against a variety of 
parasitic organisms. It is important to point out that these inhibitors are all intended 
to be specific for the target protease, even though, in some cases, the same inhibitor 




Subtilisins: an overview 
 
 Serine proteases have been extensively studied and are known to be 
involved in a broad variety of cellular processes, including protein activation, 
apoptosis, cell quality control and regulation of signaling pathways [74-79]. 
Subtilisins are a subclass of serine proteases that are structurally distinct from the 
chymotrypsin family and their similarity in function is a result of convergent 
evolution. Mainly, subtilisins drew a lot of attention because of their application in 
biochemical studies and commercial use [80-82]. Bacterial subtilisins are easy to 
express in a soluble and active form in bacterial expression systems and they can 
cleave a variety of substrates, making them suitable for commercial applications, 
specifically as detergent additives.  
 However, not all subtilisins are so easily studied by biochemical 
methods. The Bacillus amyloliquefaciens subtilisin, BPN, lacks disulfide bonds, which 
often make proteins harder to be expressed in a soluble and catalytically active form 
in bacterial heterologous expression systems [83-86]. These relatively easy-to-
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work-with proteases have been characterized at a fast rate. In the case of subtilisins 
from higher eukaryotes, working out the biochemistry of a protease  has proved to 
be much more difficult.  
 As an example, in 1999 [40, 87] two independent research groups reported a 
second subtilisin-like protease encoded in the malaria parasite genome. At the 
moment, there was a lot of interest in identifying the protease that was responsible 
for the serine protease activity that was observed to be required during red blood 
cell invasion by the malaria parasite. This protease was then rapidly targeted for the 
design of novel antimalarials. Designing an inhibitor for this specific activity could 
halt host cell invasion during the stage in which this parasite causes potentially 
lethal symptoms in humans. Since then, however, efforts in developing a 
heterologous system for the expression of catalytically active protease have not 
been successful, as reflected in the literature. This indicates that not everything is 
known about subtilisins and there is still a lot to learn about this group of serine 
proteases, otherwise we would be able to easily isolate and work out the 
biochemistry of all subtilisins.  
 
Plasmodium subtilisins 
 The malaria parasite genome includes the non-redundant single-copy 
coding sequences of three subtilisin-like proteases [88] (Figure 1.2 and Figure 1.3): 
subtilisin-like protease 1 (SUB1), subtilisin-like protease 2 (SUB2) and subtilisin-
like protease 3 (SUB3). Of these three, SUB1 and SUB2 are known to be essential for 
parasite survival during blood stages, at least. SUB1 [89-91] plays an important role 
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during egress [92, 93]. SUB3 is the most recently annotated and it does play a role 
during asexual stages but it is not essential [94, 95].  
 SUB2 has been mostly characterized in molecular biology studies during the 
last fifteen years [40, 45, 96, 97]. Because of the important roles of these proteases, 
they are considered an appealing target for the design of new antimalarials. On the 
other hand, SUB2 is also a target for vaccine development since it is exposed to the 
antibodies in the blood during the process of RBC invasion. This project is focused in 
the characterization of Plasmodium SUB2 with aims to develop novel inhibitors of 
red blood cell invasion using small molecules and for vaccine development to use 
host interfering antibodies targeting this specific protease. 
 
Subtilisin-like protease 2  
 SUB2 is the only type-1 integral membrane subtilisin-like serine protease of 
the malaria parasite. Unlike SUB1 and SUB3, SUB2 features a C-terminal 
transmembrane domain and its prodomain is relatively large compared to its 
Plasmodium paralogs and from those found in other subtilisins (Figure 1.2). It also 
has an N-terminal signal peptide for secretion onto the parasite surface, a conserved 
serine Asp, His, Ser catalytic triad in its catalytic domain, a juxtamembrane domain 
and a cytoplasmic tail. SUB2 was first identified during the asexual cycle of the 
parasite while research groups were looking to identify the serine protease 
responsible of the merozoite surface sheddase activity observed during RBC 
invasion.  
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 There is a general interest in trying to elucidate the different roles that SUB2 
may play at different stages of the parasite, especially during host cell invasion. Still, 
it is better known for its role in RBC invasion, after it was determined that SUB2 was 
responsible for the merozoite surface sheddase activity. It sheds surface adhesins 
(Figure 1.4) MSP1 and AMA1 [96] at the membrane junction during the process of 
erythrocyte invasion by juxtamembrane cleavage [98]. It has also been proposed 
that Plasmodium thrombospondin-related apical merozoite protein (PTRAMP) [99] 
is another SUB2 merozoite substrate. Access to its substrates is achieved upon 
secretion from the micronemes onto the parasite’s surface at the apical end of the 
parasite. Consequently, SUB2 translocates across the parasite surface to the 
posterior end in an actin-dependent fashion [45], presumably mediated by its 
cytoplasmic tail at the N-terminus. Throughout the course of invasion, it stays 
anchored to the merozoite membrane staying exposed to components of the 
immune system that are circulating in the blood [97]. Making SUB2 part of the 
repertoire of surface antigens at the surface of the invading merozoite.  
 Shedding of surface ligands is not the only known function of SUB2. MSP1 
and AMA1 are two substrates for its maturase activity [40, 96], for instance. Other 
roles are also attributed to SUB2 during other parasite stages as well. For example, 
in a mouse model of malaria, SUB2 was secreted onto epithelial cells by the 
Plasmodium ookinete during the invasion of the mosquito’s midgut. Following 
secretion, it was found in aggregates associated to actin cytoskeletons [100]. This 
observation suggests a direct or indirect role in cytoskeletal rearrangement. In 
addition, at a later stage in the mosquito, SUB2 was found to be present in the 
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salivary gland sporozoites [101], entertaining the idea of a possible implication in 
gliding and motility. Still, at present, the better-understood roles of SUB2 are those 
implicated in the asexual stages, even when these are not fully characterized by in 
vitro studies yet.  
 So far, we have been able to gather very important information regarding the 
function of SUB2 during blood stages mostly by molecular biology techniques. 
Sequence specificity was evaluated in recombinant parasite cultures, by mutating 
the AMA1 cleavage site sequence. These experiments showed no primary sequence 
preference for SUB2 cleavage activity. Also, the specific molecular determinants for 
SUB2 trafficking in the merozoite were solved. This work showed that it is 
transcribed directly into the endoplasmic reticulum, following by autoprocessing for 
cleavage of its cognate prodomain, to later get trafficked to the micronemes for 
secretion during RBC invasion.  
 A significant advance in SUB2 research could be accomplished by 
establishing a heterologous system for expressing catalytically active protease for 
functional studies. Moreover, the development of a SUB2-specific activity assay will 
provide a tool for further characterization of SUB2 biochemistry and for the 
development of protease inhibitors specific for its activity. Furthermore, by solving 
its structure to atomic resolution, we will have in hand accurate insights into the 
biochemical environment at the active site of SUB2, and specific features of this 
protease could be revealed as well. This biophysical approach will provide essential 
information for screening and design of SUB2-specific inhibitors and unveil precise 
sites for antigen generation. As a result, the understanding of these fundamental 
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aspects of this merozoite surface sheddase will provide information that would help 
to better understand the function of SUB2 during other stages. 
 It is easy to imagine that a pathogen will evolve to produce proteins with 
functionally distinct roles at different stages. In fact, there is evidence of SUB2 
expression during various stages of Plasmodium life cycle [97, 100, 101]. The 
relevance of these needs to be further pursued for validation and the identification 
of unknown substrates. Following this, the more we understand the role of SUB2 
during the various stages of the malaria parasite, the more we will understand the 
various functions of Plasmodium subtilisins. These studies can potentially lead to 
novel transmission control strategies, multifunctional antimalarial molecules and 





 Malaria is an infectious disease caused by Plasmodium parasites. P. 
falciparum, the most deadly species, causes severe infections resulting in more than 
500,000 deaths every year. The symptoms of malaria occur as a result of the asexual 
life cycle that consists of multiple rounds of invasion and egress from the red blood 
cells. This cycle results in increasing destruction of RBCs and triggers immune 
responses that cause fever, one of the classical malaria symptoms. By interrupting 
this cycle, parasites will stop to proliferate and the infection will come to an end. 
Subtilisin-like protease 2 (SUB2) is a serine protease required for invasion of the 
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RBC so that the parasite can enter this host cell and develop. This thesis focuses on 
the characterization of Plasmodium subtilisin-like protease 2 as a vaccine candidate 
for the antibody-mediated intervention of the parasite and target for the 
development of small molecule inhibitors of red blood cell invasion. In Chapter 2, I 
present a proof-of-principle set of experiments to test SUB2 as an antigen for 
vaccine development in a mouse model for malaria infection. Results show that 
immunization with peptides derived from SUB2 catalytic domain sequences 
attenuate Plasmodium infection in mice and lead to an increase in multiple invasion 
events. In Chapter 3, I tested a self-assembling protein nanoparticle as an antigen 
carrier for SUB2 peptide antigens using a malaria mouse model and provide an 
insightful method for data analysis to assess parasite infection status. In Chapter 4, I 
provide insights into my efforts in establishing a heterologous system for the 
expression of active Plasmodium SUB2 and to develop a SUB2-specific activity assay. 
In general, this thesis provides the first attempts in the characterization of SUB2 as a 











Credit: "Life cycle of the malaria parasite" from Epidemiology of Infectious Diseases. Available at: 
http://ocw.jhsph.edu. Copyright © Johns Hopkins Bloomberg School of Public Health. Creative 
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Figure 1.1 The life cycle of the malaria parasite, Plasmodium. This figure 
illustrates all the stages of the malaria parasite life cycle in the human and the 
mosquito hosts. Sexual development occurs in the mosquito. The mosquito passes 
on a spore like stage of Plasmodium, the sporozoite, to a human during a blood meal. 
After asymptomatic development in the liver, the parasite transforms into blood-













Figure 1.2 The three subtilisin-like proteases of the malaria parasite. 
Schematic of the three subtilisin-like proteases encoded in the Plasmodium genome. 
These are aligned by the conserved histidine at the active site, showing the 
differences in the relative distance of the restudies at the active site in the primary 
sequence of each Plasmodium subtilisin. This figure also illustrates the large 
prodomain (grey and green) present in SUB2 (PDB PF3D7_1136900), compared to 
SUB1 (PF3D7_0507500) and SUB3 (PF3D7_0507200), its juxtamembrane domain 
(purple), transmembrane region (black) and cytoplasmic tail (yellow). All three 
Plasmodium subtilisin-like proteases have an N-terminal signal peptide (cyan). Only 
P. falciparum subtilisins are shown in this figure as an example. This figure was 












Figure 1.3 Sequence conservation across the three Plasmodium subtilisin-like 
proteases. PfSUB1 structure (PDB 4lvo) was used to map conservation of amino 
sequence across PfSUB2 paralogues, using the ConSurf Server. A) Cartoon 
representation showing the canonical topology of a subtilase, the conserved active 
site residues (sticks) and calcium atoms (yellow) found in the PfSUB1 structure. B) 
Surface representation showing that the majority of conserved amino acids reside in 














Figure 1.4 SUB2 cleaves its substrates at the surface of the parasite. SUB2 (red) 
is secreted upon RBC invasion, gaining access to its substrates. Its cleavage site is 
determined by the distance from the parasite membrane, independent of the 
sequence (black arrow), releasing the ectodomain of these ligands. From left to 
right: apical membrane antigen 1 (AMA1) in green, merozoite surface protein 1 
(MSP1) in blue and Plasmodium thrombospondin-related apical merozoite protein 

















Immunization against a merozoite sheddase promotes multiple invasion of 
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 Subtilisin-like protease 2 (SUB2) is a conserved serine protease utilized by 
Plasmodium parasites as a surface sheddase required for successful merozoite 
invasion of host red blood cells and has been implicated in ookinete invasion of the 
mosquito midgut. To determine if SUB2 is a suitable vaccine target to interfere with 
malaria parasite development, we examine the effects of SUB2-immunization on the 
Plasmodium life cycle in its vertebrate and invertebrate hosts. 
 Swiss Webster mice were immunized with SUB2 peptides conjugated to KLH 
or KLH alone, and then challenged with P. berghei. To determine the effects of 
immunization on parasite development, infected mice were evaluated by blood film 
and Giemsa staining. In addition, collected immune sera was used to perform 
passive immunization experiments in non-immunized, P. berghei-infected mice to 
determine the potential role of SUB2 in parasite development in the mosquito. 
Following P. berghei challenge, SUB2-immunized mice develop a lower parasitemia 
and show improved survival when compared to control immunized mice. Moreover, 
SUB2 immunization results in an increase in the number of multiply invaded red 
blood cells, suggesting that SUB2 antibodies interfere with merozoite invasion. 
However, passive immunization experiments suggest that SUB2 may not have a 
major role in ookinete invasion. 
 By interfering with red blood cell invasion, immunization against SUB2 limits 
malaria parasite development and confers protection from severe malaria. 
Together, these results provide proof-of-principle evidence for future investigation 
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into the use of SUB2 as a vaccine or drug target to interrupt parasite development in 

























 Obligate intracellular parasites from the genus Plasmodium are the agents 
responsible for malaria, placing an estimated 3.4 billion people at risk of the disease 
throughout the world [103]. Five species of Plasmodium parasites cause human 
malaria, yet the largest impacts to public health are primarily caused by Plasmodium 
falciparum in sub-Saharan Africa, leading to approximately one million deaths every 
year [104].  
 Malaria parasites undergo a complex life cycle in their mosquito and human 
hosts, which require Plasmodium parasites to invade and replicate in multiple cell 
types and host environments. To accomplish these developmental progressions, 
Plasmodium parasites utilize specific invasion ligands and proteases to facilitate 
host cell invasion [22, 105]. Merozoite invasion of red blood cells (RBCs) has been 
studied in the most detail, and involves a large repertoire of surface proteins that 
contribute to multiple invasion pathways [22]. Similarly, recent evidence suggests 
that ookinete invasion of the mosquito midgut may also involve multiple surface 
proteins and invasion pathways [106]. While both merozoite invasion of the RBC 
and ookinete invasion of the midgut are rapid, these stages have attracted recent 
attention as targets for a blood stage [107-109] or transmission-blocking vaccines 
[110-112].  
As a shared component of merozoite and ookinete invasion pathways, 
Subtilisin-like protease 2 (SUB2) is an ideal candidate to interfere with the disease-
causing forms of malaria asexual development, as well as development in the 
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obligate mosquito host. In merozoites, SUB2 accumulates in the parasite 
micronemes and is secreted onto the merozoite surface upon schizont rupture [45]. 
There, it is believed that SUB2 interacts with an actin-dependent motor to behave as 
a sheddase, cleaving surface-bound MSP1 and AMA1 on the parasite membrane [45, 
96]. As SUB2 moves to the posterior end of the merozoite during RBC invasion, 
these substrates are cleaved at a certain distance relative to the membrane with 
minimal sequence specificity, in contrast to other proteases [45]. While little is 
known regarding SUB2 function during ookinete invasion, limited evidence would 
suggest that it is secreted by ookinetes during mosquito midgut invasion [100]. In 
cells that have undergone ookinete invasion, SUB2 is found in protein aggregates in 
close association with the actin cytoskeleton and may function to disrupt the host 
cytoskeletal network to facilitate invasion [100]. While evidence would suggest that  
SUB2 is an integral component of Plasmodium parasite development due to its 
crucial role in RBC invasion  [40, 45], attempts to further define its role in the sexual 
stages of parasite development have yet to be explored.  
Although these invasive stages are transient, both stages likely require SUB2 
activity for the processing and shedding of parasite surface ligands. Despite the 
short window of opportunity to target these stages, naturally acquired immunity 
predominantly targets proteins involved in merozoite invasion [107, 109]. Included 
among several merozoite surface antigens or proteins secreted during merozoite 
invasion, SUB2 was determined to be a strong target candidate to elicit malaria 
protective immunity [107].  
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To determine if SUB2 is a viable malaria vaccine candidate targeting both the 
asexual and sexual life cycles of Plasmodium, we designed two synthetic peptides 
representing solvent exposed regions of the P. berghei SUB2 catalytic domain to 
evaluate the effects of SUB2 immunization in mice. In the present study, we provide 
evidence that PbSUB2-immunized mice confer protective immunity from developing 
severe malaria infection by attenuating parasite growth via promoting aberrant 
merozoite invasion. Our results therefore validate SUB2 as a novel target against 
malaria infection in a mouse model system.  
 
 
Materials and Methods 
 
SUB2 homology modeling and visualization 
 Homology model of PbSUB2 (PlasmoDB code: PBANKA_091170, Gene ID: 
3423789) was generated using the I-TASSER Protein Structure and Function 
Prediction Server using default settings [113]. From all the models predicted by the 
server, the one with the highest confidence score was used in our study. Models 
were visualized using PyMol (The PyMoL Molecular Graphics System, Version 
1.6.0.0 Schrödinger, LLC). 
 
Mice 
Female Swiss Webster mice (~21-24g) were purchased from Harlan and 
maintained in accordance with the recommendations of the Guide for the Care and 
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Use of Laboratory Animals of the National Institutes of Health. All animal 
procedures were approved by the Institutional Animal Care and Use Committee of 
the Johns Hopkins University (protocol number MO09H58). 
 
SUB2 immunization  
Synthetic SUB2 peptides conjugated to keyhole limpet hemocyanin (KLH) 
through the cysteine at the N- (Sub2 Peptide #2- CRTSIKIVSKDKKTI) or C-terminus 
(Sub2 Peptide #1- KYSDRYEMTDELFDC) via a –SH bond were produced by 
GenScript Corporation (Piscataway, NJ). 
Female Swiss Webster mice (~21-24g) were primed with a 50:50 mixture 
(50 μg/mouse) of both SUB2 peptides in phosphate buffered saline (PBS) or 50 μg of 
a control KLH carrier in PBS with either complete Freund’s adjuvant (CFA) or 
incomplete Freund’s adjuvant (IFA) in a 1:1 emulsion and immunized by Intra-
peritoneal  injection (i.p.).  Mice were boosted four times in two week intervals with 
50 μg/mouse of peptide in a 1:1 emulsion with IFA via i.p. injection. Serum was 
collected from each individual mouse prior to priming, as well as the third and 
fourth boosting immunizations to monitor antibody titers. Two weeks after the final 
boosting immunization, animals were used for subsequent challenge experiments 
with P. berghei parasites. 
 
P. berghei and P. falciparum RNA Isolation and cDNA production 
P. berghei ANKA 2.34 total RNA was prepared from blood of an infected Swiss 
Webster mouse (~10% parasitemia) obtained via cardiac puncture and isolated 
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using TRIzol Reagent (Invitrogen) according to the manufacturer’s specifications. 2 
µg of total RNA was used as a template for the production of cDNA using 
SuperScriptIII (Invitrogen). 
Approximately 1 μg of total RNA from asynchronized P. falciparum 3D7 
parasites was isolated using TRI Reagent (Molecular Research Center, Inc) and 
treated with DNase I (New England Biolabs) according to the manufacturer’s 
protocol. Synthesis of complementary DNA was performed with the SuperScript 
First-Strand Synthesis System for RT-PCR (Invitrogen). 
 
Plasmodium SUB2 cloning 
 P. berghei SUB2 N476 - N1185 (PlasmoDB code: PBANKA_091170, Gene ID: 
3423789) and P. falciparum SUB2 N528 - S1135 (PlasmoDB code: PF3D7_1136900, 
Gene ID: 810927) coding sequences (see Figure 2A) were amplified using cDNA 
obtained from P. berghei ANKA 2.34 or P. falciparum 3D7 strains using the 
respective primers PbSUB2_Fwd: 5’  
CTCCATGGCGAATAATTCAAATGCATTTTTGAGTGTAGAC 3’, PbSUB2_Rev: 5’ 
ACGGATCCGTTATCATGCTCATATAAATTATATAAAGC 3’, PfSUB2_Fwd: 5’ 
ATCCATGGCGAATAATAAAAAAATTTTGTTAAATGTTGAT 3’ and PfSUB2_Rev: 5’ 
ACGGATCCACTATCATATTCATACAAATTATATAAGGC 3’.  PCR products were 
amplified using Phusion® High-Fidelity DNA polymerase (New England Biolabs) 
with an annealing temperature gradient of 52 °C – 70 °C for 30 seconds, followed by 
extension at 72 ˚C for 2 minutes.  
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SUB2 PCR products were inserted in frame using NcoI and BamHI restriction 
sites into a modified pRSF-1b vector (Novagen) for expression as an Maltose 
Binding Protein (MBP)-fusion protein with a C-terminal 6xHis tag for purification 
and detection purposes as previously described [114]. Positive clones were 
screened using colony PCR with primers described above and insertion sequences 
were confirmed by sequencing.  
 
Recombinant protein expression and purification 
  MBP-SUB2 fusion constructs were transformed into Rosetta 2 (DE3) 
competent E. coli (Novagen) for protein expression. Cells were grown in the 
presence of 1.5 % glucose and 50 µg/ml Kanamycin in 500 ml 1X Terrific Broth 
media until OD600 of ~ 3.0 and induced with a final concentration of 0.5 mM IPTG. 
Recombinant proteins were expressed overnight at 20 °C under vigorous shaking at 
250 rpm. 
 Bacteria were harvested by centrifugation at 2,500 RPM for 30 minutes at 4 
°C. Bacterial pellets were re-suspended in lysis buffer (25 mM Tris pH 9.0, 100 mM 
NaCl) and lysis was performed using an Emulsiflex C5 cells disruptor (Avestin Inc.) 
at 100 MPa. Whole cell lysates were fractionated by centrifugation at 17,000 rpm for 
1 hour at 4 °C and the supernatant was applied to an open gravity column (BioRad) 
containing 1 ml of Amylose resin (New England Biolabs) for affinity capture of the 
MBP taged fusion protein. Bound protein was washed with lysis buffer and eluted in 
the presence of 20 mM maltose. Elution samples from the Amylose resin purification 
steps were applied to an affinity column containing Cobalt-TALON resin (Clontech) 
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for secondary purification with the 6xHis tag. Bound protein was washed with lysis 
buffer and eluted with 200 mM imidazole. Elution samples were concentrated using 
Nanosep Centrifugal Devices (Sigma) with a 10 kDa cutoff.  
 
Western blots 
Approximately 1.7 μg of recombinant PbSUB2 and PfSUB2, and ~3 μg MBP 
(fusion protein only) were separated on a 12 % SDS-PAGE gel. Following 
electrophoresis, the gel was washed in diH20 for 10 minutes and equilibrated in 1X 
transfer buffer (25 mM Tris, 192 mM Glycine, 20 % methanol, 0.0375 % SDS). 
Proteins were transferred to a PVDF membrane on a Semi-dry transfer cell for 2 
hours under constant voltage (25V). After transfer, the membrane was blocked with 
5 % milk in 1X TBST for 30 minutes (250 rpm at 37 °C) and washed three times with 
1X TBST. Membranes were incubated overnight at 4 °C with serum from SUB2- or 
KLH- immunized mice at a 1:500 dilution in 1X TBST or with a mouse anti-Maltose 
Binding Protein antibody (Upstate – Millipore, #05-912)  at a 1:10,000 dilution in 1X 
TBST.  After three washes with 1X TBST, membranes were incubated with an 
alkaline phosphatase-conjugated goat anti-mouse antibody (1:5,000 dilution in 1X 







Plasmodium challenge in SUB2 immunized mice 
 Following immunization with either the CFA or IFA protocols described 
above, SUB2 or control KLH mice were infected with ~2x102 P. berghei mCherry 
[115] asexual parasites via intra venous (IV) injection as previously performed 
[116]. To monitor parasite growth, thin smears of tail blood were stained with 
Giemsa and examined under a microscope to determine parasitemia (% of infected 
erythrocytes) every day for ten days.   
 To determine the effects of immunization on mouse survival following the 
above Plasmodium challenge, the survival of immunized mice was monitored for 40 
days following the initial infection. 
 
Multiple Invasion Analysis 
 Ten days after infection with P. berghei, Giemsa-stained thin smears from 
SUB2 or KLH immunized mice with measurable parasitemia were analyzed by light 
microscopy. Independent of parasitemia, approximately 200 infected RBCs were 
examined per mouse to determine the number of infected RBCs that contain one or 
more parasites.  The number of single, double, or multiple invasion events are 
reflected as percentages of the total number of infected RBCs. Mann-Whitney tests 
were performed using GraphPad Prism to determine significance.    
 
Passive immunization experiments 
Swiss Webster mice infected with the mCherry strain of P. berghei [115] 
were examined for similar levels of exflagellation three days after inoculation as 
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previously described [112]. Mice with matching infections were anesthetized and 
used for blood feeding control (pre-KLH) or treatment (pre-SUB2) groups of An. 
gambiae mosquitoes for 15 minutes. The anesthetized mice were then taken off the 
cage and passively immunized (i.v.) with KLH or SUB2 immune sera (final 
concentration of 2 mg/ml) and allowed to recover for 15 minutes. The passively 
immunized mice were then fed to sibling groups of An. gambiae mosquitoes for an 
additional 15 minutes to measure any effects on parasite development in the 
mosquito.  
Following feeding, mosquitoes were incubated at 19°C to promote P. berghei 
development. Mosquito midguts were dissected 7 days post-blood meal (PBM), and 
oocysts numbers were counted using a compound fluorescence microscope. The 
results of two independent experiments were analyzed by Mann-Whitney using 





Structural modeling of P. berghei SUB2 catalytic domain 
A structure model was predicted for the catalytic domain of PbSUB2 by the I-
TASSER server and contains a secondary structure topology characteristic of 
subtilisin-like serine proteases (Figure 2.1A). The amino acid residues that comprise 
the catalytic triad Asp 705, His 748 and Ser 911 required for catalysis are positioned 
at the active site of the model (Figure 2.1A). Comparing our predicted model using 
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the EBI SSM webserver, the closest structural homolog in the Protein Data Bank 
(PDB) is the subtilase, thermitase (PDB 1twc:E) from Thermoactinomyces vulgaris. 
With an overall root mean square deviation (R.M.S.D) of 1.4 Å for 247 amino acid 
residues as determined with PDBeFold [117], our predicted structural model for 
PbSUB2 therefore has a high confidence level, resembling the overall known fold of 
other subtilases. 
 
Design of P. berghei SUB2 peptides 
Using proprietary software (GenScript), highly antigenic peptides 
corresponding to the PbSUB2 catalytic domain were identified. To test these 
candidate 14 amino acid peptides, the corresponding regions were mapped on a 
PbSUB2 catalytic domain homology model. Two peptides mapping to opposite 
flexible solvent exposed regions of PbSUB2 were selected to increase the likelihood 
that antibodies generated against these peptides would interact with the protease 
on the surface of merozoites or ookinetes during invasion (Figure 2.1A). Peptide #1 
and #2 target unique solvent accessible regions of the catalytic domain of PbSUB2 
(Figure 2.1B, left). 
The sequence of Peptide #1 is nearly identical (93 %) to the corresponding 
region of P. yoelii SUB2 (Figure 2.1B, right). The two sequences only differ by the 
amino acid at position Leu 734 in the P. berghei sequence and Phe 734 in P. yoelli, 
suggesting a high level of conservation between the rodent malaria species.  Less 
conservation exists between Peptide #1 and the human malaria parasites (P. 
falciparum, P. vivax, and P. knowlesi), with only 64% similarity (36% ID) to P. 
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falciparum (Figure 2.1B). However, the Peptide #2 sequence alignment reveals more 
conservation and sequence similarity across Plasmodium species. The P. berghei and 
P. falciparum SUB2 sequences show 85% similarity (71% ID), while the rodent 
malaria parasites are completely conserved (Figure 2.1B). Both peptide sequences 
map to regions of the PbSUB2 catalytic domain (Figure 2.2A). 
 
Mice immunized with SUB2 peptides recognize recombinant PbSUB2 
MBP-SUB2 expression constructs containing a short region of the pro-
domain and the entirety of the SUB2 catalytic domain (Figure 2.2A) were expressed 
using a Rosetta2 E. coli heterologous system. Recombinant SUB2 was visualized as a 
single band for PbSUB2, or as two bands for PfSUB2, of approximately 110 kDa full-
length protein products (Figure 2.2B). Smaller protein products are likely the result 
of sample degradation during the purification process or translational truncation 
products that were observed for both SUB2 constructs (Figure 2.2B). Both full-
length and truncated forms of SUB2 were detected using an MBP antibody, 
confirming the detection of the recombinant MBP-SUB2 fusion protein products 
(Figure 2.2B).  When incubated with immune sera from SUB2-immunized mice, 
recombinant PbSUB2 is detected in full length and degraded forms while only a faint 
band corresponding to full length recombinant PfSUB2 protein was detected (Figure 
2.2B).  Importantly, mice immunized with KLH alone did not recognize either 
recombinant SUB2 protein (Figure 2.2B).  
These results confirm that antibodies were generated in mice immunized 
with PbSUB2 peptides that can sufficiently recognize recombinant PbSUB2 (Figure 
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2.2B). Furthermore, immune sera raised against PbSUB2 peptides specifically 
targets PbSUB2 and does not cross-react with P. falciparum SUB2 (Figure 2.2B), 
suggesting that the conservation in the peptide sequences is inadequate for cross-
species protection. However, future immunization experiments are needed to 
determine the properties of the individual peptides and whether they are capable of 
cross-species immune recognition of different Plasmodium species.  
 
SUB2-immunization attenuates asexual Plasmodium development 
 To monitor the effects of immunization on parasite development, KLH- and 
SUB2-immunized (IFA or CFA) mice were challenged with ~2x102 P. berghei 
parasites by intravenous injection and the parasitemia was monitored over the 
period of ten days. Blood stage infections were detected in 17 of 18 mice, and little 
variation was seen between mice immunized with the IFA or CFA immunization 
protocols (Table 2.1). As a result, both immunization experiments were pooled for 
analysis and summarized in Table 2.1. Compared to control KLH-immunized mice, 
SUB2-immunized mice showed a slight, but not significant delay in the pre-patency 
of infection (Table 2.1).  However, when the parasitemia was monitored over the 
period of ten days, asexual growth was significantly attenuated following SUB2-
immunization (Figure 2.3A).  
 In SUB2-immunized mice, parasite growth was reduced by 37, 43, and 56% 
from days 8-10, effectively reducing parasitemia more than two fold when 
compared to KLH control mice (Figure 2.3A). In addition, nearly half of the SUB2-
immunized mice (4 of 9) had cleared all signs of parasite infection by Day 10 (Figure 
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2.3B and Table 2.1).  None of the KLH-immunized mice infected with P. berghei were 
able to clear the infection over the duration of the experiment (Figure 2.3B and 
Table 2.1). 
 
SUB2-immunization increases mouse survival after P. berghei challenge  
 Since P. berghei asexual development is attenuated in SUB2-immunized mice 
(Figure 2.3A), we wanted to explore whether SUB2-immunization also protects mice 
against malaria lethality through the decreased parasite burden. 
  To measure survival, KLH- and SUB2-immunized mice were monitored for 
forty days following P. berghei challenge (Figure 2.3C). In our experiments, SUB2-
immunized mice showed increased survival over control KLH-immunized mice 
(Figure 2.3C and Table 2.1) On average, SUB2-immunized mice survived for more 
than one week longer than KLH control mice (Table 2.1), and 7 of 9 mice survived 
the duration of the experiment (Figure 2.3C). In contrast, only 1 of the 8 infected 
KLH mice survived the entire forty day period (Figure 2.3C). This would suggest that 
the attenuated malaria parasite growth seen in SUB2-immunized mice (Figure 2.3A) 
also translates to an increased survival following P. berghei challenge (Figure 2.3C).  
 
SUB2-immunization promotes aberrant red blood cell invasion  
 Based upon observations measuring the parasitemia of the immunized mice 
(Figure 2.3A), there appeared to be a noticeable increase in the number of infected 
RBCs with multiple parasites in SUB2-immunized mice.  To quantify these presumed 
defects in invasion, the percentages of infected RBCs that had one, two, or multiple 
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(3+) parasites were measured in KLH- and SUB2-immunized mice (Figure 2.4). 
Validating our previous observation, SUB2-immunized mice had a significant 
decrease in the number of infected RBCs that had undergone a single invasion event 
when compared to KLH-control mice (Figure 2.4). We also measured a 
corresponding increase in the number of double or multiple invasion events (3+) 
following SUB2 immunization (Figure 2.4).  
Based upon these data and the important functional role of SUB2 in RBC 
invasion [40, 45], we conclude that SUB2-immunization interferes with merozoite 
invasion. Although it is not completely understood how SUB2-immunization might 
influence the production of these aberrant invasion events, previous studies using 
antibodies to merozoite surface proteins similarly report phenotypes promoting 
multiple invasion  [118, 119].    
 
SUB2 immune sera does not interfere with ookinete invasion in passively 
immunized mice  
 One previous study has reported that SUB2 is expressed by ookinetes, 
implicating that SUB2 may be secreted into the cytoplasm of ookinete-invaded cells 
as the parasite traverses the midgut epithelium [111]. Immunofluorescence staining 
identified SUB2 protein aggregates in close proximity to the actin cytoskeleton that 
suggest SUB2 may play an important role in cytoskeleton modifications during the 
process of ookinete invasion [100].    
To address the role of SUB2 in ookinete midgut invasion and the potential 
role that SUB2 immune sera could also inhibit ookinete invasion, we performed 
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passive immunization assays to determine the effects on parasite development in 
the mosquito.  As expected, passive immunization with the control KLH immune 
sera did not significantly alter Plasmodium oocyst numbers (Figure 2.5).  Similarly, 
passive immunization with SUB2 immune sera did not significantly alter oocyst 
numbers (Figure 2.5), suggesting that SUB2 may either not be required for ookinete 
invasion of the mosquito midgut or that our immune sera was present in sub-
optimal levels needed to inhibit ookinete invasion.  These research questions 
highlight the need for further investigation into the role of SUB2 during the 





Although more than 40% of the world’s population is at risk of malaria 
transmission, only limited resources exist to readily combat Plasmodium parasites. 
Current drug therapies face the ever-increasing risk of resistance [120], and  while 
multiple approaches have thus far been employed to create a malaria vaccine, they 
have had  only mixed results in clinical trials [121]. As a result, new strategies to 
reduce malaria transmission are desperately needed.  
Plasmodium species utilize many different proteases during their complex 
life cycle in the human and mosquito hosts, and serve as optimal targets to interfere 
with malaria transmission.  Previous reports have demonstrated the required role 
of a Plasmodium subtilase (SUB2) for asexual development through its role as a 
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sheddase required for merozoite invasion [40, 45]. Additional studies have also 
implicated SUB2 in ookinete invasion [100], thus making SUB2 an attractive target 
to interfere with parasite development in both its human and mosquito hosts. 
Using a rodent model, we address the potential of targeting SUB2 by 
immunizing mice against specific SUB2 derived peptides.  When compared to 
control KLH-immunized mice, SUB2-immunization resulted in a slight delay in pre-
patency, decreased parasitemia when monitored over a ten day period, and 
increased survival following infection.  Similar results were obtained independent of 
the method of immunization, suggesting that the effects of immunization are 
primarily that of the SUB2 antigens and not from non-specific effects mediated by 
the CFA. Together, these data would suggest that SUB2-immunization greatly 
impairs parasite growth, likely by interfering with the efficacy of merozoite 
invasion. 
In support of this idea, we detected an increase in the number of multiply 
invaded RBCs following SUB2-immunization, suggesting that merozoite invasion is 
significantly altered. Similar effects have been seen in other studies using antibodies 
targeting merozoite proteins, where it was proposed that multiple invasions are the 
result of merozoite agglutination [118, 119]. According to this hypothesis, the 
invasion of some merozoites may be completely blocked, while incomplete 
inhibition may result in multiple parasites that have been cross-linked by SUB2 
antibodies that undergo invasion together as a complex or dissociate once the RBC 
surface has been recognized.  Due to the short time frame in which merozoites 
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undergo release and invasion into new RBCs, the concentration and rate of antibody 
binding may be critical factors in invasion inhibition.  
Very little information exists regarding the viability of infected RBCs that 
have undergone multiple invasion events. It has been hypothesized that nutritional 
and structural limitations following multiple invasion may reduce the production of 
viable merozoites [118], thus raising the possibility that these infected RBCS may be 
a “dead-end” for the parasite.  As a result, the higher incidence of multiple invasions 
may have a significant contribution to the decreased parasitemia and increased 
survival in the SUB2-immunized mice within our study. 
While the increased survival of SUB2-immunized mice would suggest that 
SUB2 immunization can confer protection to the severe forms of malaria infection, 
we did not attempt to differentiate the potential reasons for morbidity in our 
Plasmodium infected mice. Visible neurological symptoms of cerebral malaria (as 
defined by [122]) were not observed, leading us to believe that infection-induced 
mortality was due to other malaria-related causes.  
Based upon previous studies implicating SUB2 in ookinete invasion [100], we 
tested the ability of our SUB2 antibodies in passive immunization assays to examine 
the role of SUB2 on parasite development in the mosquito.  Although we did not 
detect any differences in oocyst development, it still remains unclear what role 
SUB2 may have during the process of ookinete invasion.  Given the limited amount 
of immune sera produced, only one concentration was tested in the passive 
immunization experiments and these may have been suboptimal concentrations to 
inhibit ookinete invasion.  Alternatively, the production of SUB2 by ookinetes may 
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not be integral to ookinete motility within the mosquito midgut and may not be a 
viable target to interfere with malaria transmission.  As a result, the role of SUB2 in 
Plasmodium ookinetes requires future study. 
In summary, our experiments indicate that immunization against a 
merozoite sheddase can interfere with Plasmodium development in mice.  While 
these results are still preliminary using a rodent malaria model, our data provide 
strong evidence for future investigation into the use of SUB2 as a vaccine or drug 
target to interrupt parasite development in more relevant human malaria models. In 
support of this idea, epidemiological studies in Papua New Guinea indicate a strong 
correlation between the detection of SUB2 antibodies and naturally acquired 
protective immunity [107] [7]. Similar studies with blood samples from field 
isolates of African populations to determine the role of SUB2 in naturally acquired 
immunity could provide further verification for this promising approach as a 
vaccine candidate. As a result, future experiments will address challenges to 
increase the efficacy of our approach to inhibit SUB2 function using monoclonal 


















Figure 2.1 Pb SUB2 homology models identify peptide targets for 
immunization. (A) Cartoon (left) or surface representation (right) homology model 
of the PbSUB2 catalytic domain (residues L672-L971). Regions corresponding to 
Peptide #1 (purple) and Peptide #2 (green) were used for immunization 
experiments. Catalytic residues Asp705, His748 and S911 in the active site pocket 
are shown as orange, cyan and red spheres, respectively. (B) Lateral view of Peptide 
#1 (purple) and Peptide #2 (green) in the PbSUB2 surface representation model 
reveals that each peptide corresponds to solvent exposed areas (left). Sequence 
alignments of both peptide sequences with corresponding regions of P. falciparum, 




Figure 2.2 Production of recombinant SUB2 and recognition using Sub2 
immune sera. (A) Domains of endogenous PbSUB2 (top): signal peptide, pro-
domain, catalytic domain with catalytic residues Asp (orange), His (cyan) and Ser 
(red), transmembrane domain and cytoplasmic tail. Residues at the beginning and 
end of each domain are shown. Representation of recombinant PbSUB2 (middle) 
containing a minimal inhibitory domain and the full catalytic domain. Below, 
PbSUB2 Peptides #1 (purple) and #2 (green) are aligned to endogenous PbSUB2 
and rPbSUB2 with peptide sequences. (B) Recombinant proteins maltose binding 
protein (MBP), PbSUB2 or PfSUB2 MBP-fusion proteins SDS-PAGE stained with 
Coomassie and Western Blot results. Arrows denote full length PbSUB2 and PfSUB2 
























Figure 2.3 SUB2 immunization reduces the intensity of Plasmodium berghei 
infection and increases mouse survival. The parasitaemia of KLH- or SUB2-
immunized mice was determined over the period of ten days after infection with P. 
berghei parasites (A). Each point represents the mean parasitaemia (n = 9) with 
error bars displaying standard errors of the mean and the asterisk denoting 
significance (P = 0.0042). The scatter plot displays the parasitaemia at day 10, with 
each point representing the parasitaemia of individual KLH- or SUB2-immunized 
mice (B). The red bar represents the median of each experiment with the asterisk 
denoting significance (P < 0.05). The survival of KLH- and SUB2-immunized mice 
was monitored over the course of forty days following P. berghei challenge (C). The 
number of surviving mice for each treatment over the duration of the experiment is 
displayed as a percentage of the total number of infected mice at a given time point. 











Figure 2.4 SUB2-immunization promotes multiple invasion of red blood cells. 
Representative images of single, double, or multiple invasion (3+) events in P. 
berghei-infected red blood cells are depicted with their corresponding percentages 
in KLH- (black) or SUB2- (grey) immunized mice at ten days post-infection. The 
percentage of each invasion phenotype is displayed as the mean and standard error. 













Figure 2.5 Passive immunization with SUB2 immune sera does not influence 
parasite growth in the mosquito. Oocyst numbers were measured to determine 
the effects of passive immunization to control KLH- or SUB2-immune sera. 
Plasmodium berghei-infected mice were fed to mosquitoes and oocyst numbers 
were determined for each experimental group before passive immunization (pre-
KLH or pre-SUB2), or following passive immunization (KLH or SUB2). The total 
number (n) of mosquito midguts examined is displayed under each experimental 
group. The red bar denotes the median of each experiment. No significant (ns) 






























 Subtilisin-like protease 2 (SUB2) is a conserved essential serine protease that 
functions as a merozoite surface sheddase (MeSh) during red blood cell invasion by 
Plasmodium parasite merozoites. To execute this role, SUB2 is secreted onto the 
surface of the parasite getting exposed to the antibodies circulating in the blood, 
kept anchored to the parasite membrane. As a parasite surface protein, SUB2 is part 
of the assortment of surface antigens and can be targeted for antibody-mediated 
inhibition. In a proof-of-principle experiment, immunization against this 
Plasmodium subtilisin resulted in attenuation of malaria infection in mice. 
 To further characterize and optimize antibody-mediated inhibition of 
Plasmodium blood stages by targeting SUB2, a self-assembly protein nanoparticle 
(SAPN) alone or presenting either SUB2-Peptide1 or SUB2Peptide1+Peptide2 was 
developed. The SAPNs were used to immunize BALB/c mice; similarly to what is 
described in Chapter 2 but with important differences. Besides the use of SAPN for 
antigen delivery, the additional main differences are: an adjuvant was not used for 
SAPNs immunizations only two, instead of four boosts were performed and no 
carrier protein was employed in this experiment.  
 Additionally, on this follow-up approach, a specific number of mCherry P. 
berghei ANKA infected A. stephensi female mosquitoes were used for natural 
inoculation-challenge of each mouse individually. The amount of mosquitoes 
containing blood after the challenge was also determined. This step was recorded on 
video for verification of feeding events on each mouse. Any mouse with no blood-
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positive mosquitoes was removed from the malaria infection analyses. The progress 
of the infection was determined by quantifying the percentage of parasitized cells 
using an ImageStream instrument and the IDEAS software. Additionally, visual 
confirmation by blood film and Giemsa staining were performed. Immune sera from 
each mouse were collected prior the challenge and with last surviving mice at the 
end of the experiment for immunoblotting confirmation for antibody production. 
 Results revealed no significant difference in the progress and severity of the 
parasite infection among the three groups of infected mice from which two or more 
mosquitoes fed, in general. However, In the case of a mouse with only one blood-
positive mosquito, no detectable levels of parasitized cells were found with the 
ImageStream analysis. Only one control mouse showed a significantly higher level of 
parasitemia compared to the other groups. The mean parasitemia of SAPN-
SUB2Peptide1 immunized mice was slightly lower than SAPN control and SAPN-
Peptide1+Peptide2 combination. The difference between the groups is not 
significant with P value 0.5097 (Kruskal-Wallis test). 
 These results indicate that SAPN-mediated immunization is not sufficient for 
protection against malaria with targeting SUB2 under the conditions tested in this 
experiments. Repeating this experiment with some modifications may improve the 
results and permit us to characterize the effect in protection by each SUB2 peptide. 
It is possible that a SAPN-based vaccine would have to be optimized for each antigen 
of choice for optimal protection. Nonetheless, immunoblotting shows that 
recombinant SAPN harboring either SUB2 Peptide 1 or the combination of Peptide 1 
and Peptide 2 is recognized by anti-SUB2 antibodies generated upon immunization 
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with the same KLH-conjugated SUB2 peptides from previous proof-of-principle 
experiment (Chapter 2). This indicates that using SAPN for displaying these 
peptides does not affect how they interact with antibodies.  Furthermore, results 
show that these antibodies can detect both SAPN-SUB2Peptide1 and the SAPN-
SUB1Peptide1+Peptide2, but a stronger signal was observed for SAPN-
SUB2Peptide1, suggesting that antibodies present in the mouse sera of mice 
immunized with KHL-conjugated peptides have a higher presence of anti-Peptide1 
antibodies which would result in better neutralization. Further studies are required 


















 Malaria is a potentially fatal disease caused by parasites of the genus 
Plasmodium. Disease burden and deaths have decreased during the past decade[1] 
due to a combination of malaria prevention and control measurements. Still, 
approximately 500,000 deaths are attributed to malaria every year[1]. One of the 
factors that challenge the efforts of controlling malaria is the emergence of drug 
resistant strains and the lack of an effective vaccine. Thus, there is a need of novel 
molecular drug targets and vaccine candidates to overcome parasite drug-resistance 
and improve the efficacy of a malaria vaccine. 
 We previously showed that immunization against Plasmodium subtilisin-like 
protease 2 (SUB2) attenuates malaria infection [123] when mice were immunized 
with two SUB2 peptides. It is uncertain, however, if both peptides are necessary to 
provide protection or if either is sufficient. Characterization of individual SUB2 
peptides protection may lead to a better understanding of the requirements of 
SUB2-targeted protection and antibody-mediated inhibition of red blood cell 
invasion. 
 Protection from malaria has been studied using self–assembling protein 
nanoparticles (SAPN). SAPN fused to RTS,S target circumsporozoite protein (CSP) 
was shown to induce an immune response generating antibodies that were effective 
in inhibition P. falciparum sporozoite invasion in cultures [124]. These particles 
function as a repetitive antigen display [125-127] technology that can be used for 
presenting antigens to the immune system. SAPN are expressed and purified as a 
 58 
fusion protein of the target of interest [126]. A detailed protocol for expression and 
purification has been developed [126], allowing us to quickly advance into studies of 
characterization of new vaccine targets and the optimization of their use in a mouse 
model of malaria. 
 Chapter 2 discusses the effects protection when mice are immunized against 
SUB2 using two different peptides. This proof-of-principle experimented resulted in 
the attenuation of malaria parasite infection in SUB2-immunized mice compared to 
controls. However, the antigenicity of each individual peptide was unclear. In 
addition, protection did not lead to clearance of the infection in every case, requiring 
follow-up to pursue optimal results. 
 To understand the effect in protection by each individual peptide targeting 
SUB2 surface-exposed catalytic domain SAPN harboring SUB2 peptides were used 
to immunize mice in the absence of an adjuvant or a carrier protein. In this 
experiment, three SAPNs were used: SAPN-SUB2Peptide1, SAPN-SUB2Peptide1+2 
and SAPN only to compare the protection by the different SAPNs and determine if 
immunization with a single peptide is sufficient. Following immunizations, mice 
were challenged with mCherry P. berghei parasites via natural inoculation with 
Anopheles stephensi mosquitoes. The challenge was video recorded for verification 
of results and mosquitoes were evaluated to confirm feeding on the mice. The 
percentage of parasites circulating in the blood was determined by Image Stream 
analysis. Mouse survival was monitored as an indicator of the severity of the 
infection. Antibody production by each mouse was verified by immunoblotting. 
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 Results show that the different SAPNs were not sufficient to elicit an immune 
response that would result in the production of antibodies without the use of an 
adjuvant or a carrier protein. However, when tested with mouse sera from KLH 
immunized mice (Chapter 2), both SAPN-SUB2Peptide1 and SAPN-SUB2Peptide1&2 
were recognized with the antibodies in these samples. These results demonstrate 
that antibodies against PbSUB2 peptides from the previous experiments recognize 
SUB2 peptides displayed by the SAPN.  
 
 
Methods and Materials 
 
Expression, purification and assembly of SAPNs 
 All the three SAPNs (Figure 3.1) were expressed and purified as described on 
McCoy M.E. et.al, 2013 [126]. Final protein concentrations were 0.0268 mg/ml of 




 Female BALB/c mice (~20g) were purchased from Harlan. These mice were 
maintained according to the recommendations of the Guide for the Care and Use of 
Laboratory Animals of the National Institutes of Health. All animal procedures were 
approved by the Institutional Animal Care and Use Committee of the Johns Hopkins 
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University (protocol number MO09H58). The groups of mice that were used are 
described in Figure 3.2. 
 
Immunizations 
 Approximately 20 μg of SAPN alone, SAPN-Peptide1+Peptide2 combination 
or SAPN-Peptide1, were used to prime female BALB/c mice (~20g) without any 
adjuvants. In two-week intervals, all mice were boosted two times with 20 μg of 
SAPN alone, SAPN-Peptide1+Peptide2 combination or SAPN-Peptide1. Before 
priming, serum from each mouse was collected.  
 
P. berghei challenge by natural inoculation with mosquitoes 
 BALB/c female mice were each inoculated with 10 A. stephensi mosquitoes 
infected with mCherry P. berghei parasites (Figure 3.3A). The infected starved 
female mosquitoes were added into a cardboard cup with a net covering the top and 
the bottom. 23 cups were placed on top of a clear shield and a sedated mouse was 
placed on top of each cup for 30 minutes. A camera was placed at the bottom of the 
clear shield to record the feeding of the mosquitoes (Figure 3.3B). After feeding was 
completed the mosquitoes were collected and saved in microcentrifuge tubes for 
storage at -20 °C. Figure 3.3 details the set up of the mosquito feeding experiment. 
 
Parasitemia 
 Approximately 20 μl of blood from each mouse were collected into a 
microcentrifuge tube containing 200 μl of heparin solution and kept on ice. After 
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centrifugation at 5,000 rpm for 5 minutes, the heparin solution was removed by 
aspiration. Next, blood cells were fixed in 100 μl of 4% paraformaldehyde (PFA) in 
phosphate-buffered saline (PBS) for 1 hour. After incubation, PFA solution was 
removed after centrifugation and the fixed cells were washed with PBS. Following 
the wash step, cells were resuspended in 100 μl PBS and stored at 4 °C.  
 The percentage of parasitized red blood cells in the blood samples of the 
mice was determined with Amnis ImageStream system and analyzed with IDEAS 
software following the specifications in the user’s manual. First, cells that were best 
in focus were gated. Second, single cells were gated based on the bright field Area 
versus the Aspect Ratio of the cells that were on focus from step 1. Third, the 
subpopulations were assigned based on the Hoechst DNA dye and mCherry signals. 
Positive cells for both Hoechst and mCherry were considered parasitized.  
 Giemsa-stained blood film samples were also performed and stored for 
verification purposes. 
 
Expression and purification of recombinant PbSUB2 
 Recombinant PbSUB2 was expressed and purified as described in Chapter 2. 
In this case, with the Cobalt-TALON affinity purification step was omitted. Protein 
was eluted with 20 mM maltose in 13 mM HEPES pH 7.5, 250 mM NaCl, 0.5 mM 
βME. 6 ml of pooled elution samples had a final protein concentration of 0.75 mg/ml 





 Blot  #1.  ~18 μg of rPbSUB2 were added to a nitrocellulose membrane (Bio-
Rad) that was cut and placed inside a 24-well plate. Samples were blocked overnight 
with 5 % bovine serum albumin (BSA) in 1X TBST at 4 °C. Blocking was followed by 
three washes with 1X TBST at 90 RPM for 10 minutes each. As the primary antibody, 
1:200 of mouse sera was used and incubated for 1 hour at 37 °C shaking at 50 RPM. 
Then, all samples were washed three times to remove excess antibody using 1X 
TBST. An alkaline phosphatase (AP)-conjugated rabbit anti-mouse antibody was 
used as secondary antibody. Colorimetric detection of the secondary antibody was 
done with BCIP and NBT AP substrates (Promega). 
 Blot #2. 1 mg of SAPN alone, SAPN-Peptide1+Peptide2 combination or SAPN-
Peptide1 was added to a nitrocellulose membrane as described above. Blocking, 





P. berghei challenge with mosquitoes 
 To verify that P. berghei infected A. stephensi mosquitoes were feeding on the 
mice, this inoculation step was recorded on video and the mosquitoes used in the 
experiment were stored for analysis. The video shows that all mice were bitten by at 
least one mosquito except for mouse Peptide 1 #3. Furthermore, no mosquitoes 
were observed to feed on this mouse on the movie and no blood was present in any 
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of the mosquitoes intended to inoculate this mouse. There was also no blood found 
in the tube were the mosquitoes were stored. On average, 8.3 mosquitoes fed on 
each SAPN control mice, 6.3 on the SAPN-Peptide1+Peptide2 combination, 4.6 
SAPN-Peptide1 mice (5.6 without including mouse Peptide 1 #3) and 5.3 on the 
naïve mice. The number of mosquitoes that fed on each mouse is shown in Table 1. 
 
Plasmodium infection progresses similarly in all groups infected of mice 
 The protective effects of immunizing with SAPN, SAPN-SUB2Peptide1 and 
SAPN-SUB2Peptide1+Peptide2 were examined by analysis of mouse blood samples 
on an ImageStream (Figure 3.4). Samples were taken every day from day 5 after 
challenge with P. berghei to monitor the percentage of parasitized cells through the 
course of 23 days. Blood stage parasites were detected in all mice that were bitten 
by mosquitoes, except for mouse Peptide1 #2 that never showed detectable levels of 
parasitemia. However, analysis of a blood smear sample of this mouse revealed a 
red blood cell with a ring-like structure inside (Figure 3.5). Including this mouse, 22 
out of 23 mice were effectively infected with P. berghei during the challenge and 1 
out of the 22 infected mice did not develop parasitemia to detectable levels.  
Average parasitemia values at day 10 post-infection (Figure 3.4B) were ~5 for 





Mouse survival is not affected upon SAPN-SUB2 immunization compared to 
control  
 To determine the effects of SAPN-SUB2 immunization in mouse survival as 
an indication of the severity of malaria infection, the survival of immunized mice 
was observed up to 30 days post-infection (Figure 3.6). At day 30, mice Peptide1 #2, 
Peptide1 #3, Control #3 and Control #5 were subjected to cardiac puncture 
terminal blood collection for using sera in immunoblotting experiments and 
additional analyses. 
 In this immunization experiment, results indicate that there is increased 
survival associated with SAPN-Peptide1 and SAPN-Peptide1+Peptide2 
immunization compared to SAPN-only (Figure 3.6). 100 % of SAPN-
Peptide1+Peptide2 mice were dead by day 23 post-infection and all SAPN-Peptide1 
mice were dead by day 25 post-infection, except for mouse SAPN-Peptide1 #2 and 
#3. These two did not have any detectable levels of parasites in the blood (Figure 
3.5). However, 33% of control SAPN-only mice survived until day 30 post-infection, 
when their blood was collected by cardiac puncture. These control mice were very 
sick and would probably not have lasted for more than 2 additional days. 
 
SAPN alone is not sufficient for efficient generation of anti-SUB2 antibodies 
under the conditions tested 
 To confirm that antibodies against PbSUB2 were present in mice sera after 
immunizations, two different immunoblots were performed. One of these dot blots 
consisted in utilizing recombinant PbSUB2 for detection of anti-SUB2 antibodies 
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(Figure 3.7). The other was used to determine if antibodies against the SAPN only, 
SAPN-Peptide1 or SAPN-Peptide1+2 respectively were generated (Figure 3.8).  
 Results show no signal with mouse sera against recombinant MBP-fusion 
PbSUB2 for all mouse sera samples. Positive controls using anti-MBP and mouse 
sera from KLH-conjugated SUB2 peptides (Chapter 2) confirm that all the other 
components of the assay were working properly.  
 When mouse sera used against the same SAPN it was immunized with, with 
the exception of control mice SAPN-only #4 and #5, the infected mice did not 
generate antibodies against the different SAPN antigens (Figure 3.8). Therefore, no 
antibodies against PbSUB2 were generated upon immunizations in this experiment. 
Nevertheless, when serum from KLH-conjugated mice (Figure 2.2) was used against 
either SAPN-Peptide1 or SAPN-Peptide1+Peptide2, the results were positive with a 
stronger signal on the SAPN-Peptide1 sample (Figure 3.8). Demonstrating that anti-
SUB2 antibodies can interact with SUB2 peptides displayed using a SAPN. 
 Together, these results strongly suggest that there was no difference 
between SAPN control and SAPN-SUB2 mice because no antibodies were generated 
against the antigen whatsoever; thus, there were no protective antibodies targeting 
SUB2. In contrast, the samples using mouse serum from the KLH-SUB2 peptides 








 Despite the global efforts in controlling malaria, there is still a lot of work to 
do for successful malaria control and to contemplate the ultimate goal of malaria 
eradication. Complete elimination of malaria will prevent about 500,000 deaths 
caused by this infectious disease every year[1]. To succeed in fighting malaria, we 
need novel effective drugs and vaccines. 
 A rational approach by targeted design of inhibitors provides the advantage 
of knowing the basics of the molecular target by which the approach works. Instead 
of working with an unknown target that requires identification and further 
characterization. In the present study, subtilisin-like protease 2 (SUB2) is targeted 
for antibody-mediated inhibition of invasion of the erythrocyte by the malaria 
parasite (antibody mediated protein-protein interaction inhibition). As an antigen-
delivery mechanism, a self-assembling protein nanoparticle (SAPN) [126] is 
employed for displaying of various copies of SUB2 peptides that were previously 
shown to reduce malaria infection in a mouse model of malaria infection. SAPN was 
previously used for studying the protective immune mechanism induced by 
circumsporozoite (CSP) protein[124, 128], a key component in the current vaccine 
candidate for malaria, RTS,S [10].  
 Here, in a similar approach to the one described in Chapter 2, mice were 
immunized with a SAPN-fusion protein (Figure 3.1) displaying SUB2 Peptide 1 or 
SUB2 Peptide 1 (Figure 2.1) and Peptide 2 combination (SAPN-Peptide1 and SAPN-
Peptide1+Peptide2 respectively) or SAPN alone as a control to further examine 
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antibody-mediated inhibition of parasite development within the blood.  Another 
purpose of this immunization-based experiment was to set the basis of SUB2-
targeted immunization to determine the optimal procedure to achieve protective 
immune response for the clearance or prevention of malaria infection. Other 
components were also modified to assess in the analysis of the data.  
 An important modification to the experiments with the KLH-conjugated 
peptides is that, in the current experiment, inoculation of mice with P. berghei was 
done via mosquito feeding. This is the natural course of malaria transmission to the 
vertebrate host. We were also interested in evaluated SUB2 immunization for, not 
only treatment but also prevention of infection prior to liver stages or before the 
infection establishes within the blood.  
 In general, results of this experiment remain inconclusive since, under the 
conditions tested, the use of SAPN for immunization with SUB2 peptides was not 
effective in eliciting an immune response leading antibody generation (Figure 3.7). 
There are several possible explanations to why the results were not as predicted. 
One of them is that the use of an adjuvant may be required for generating antibodies 
against SUB2 using these two peptides as antigens. It is also possible that KLH was 
playing an important role as a carrier protein in previous experiments Another 
possibility is that a higher amount of protein or additional boosts were required for 
the desired results. It could also be that a combination of more than one of the above 
is required for effective protection using SUB2 peptides #1 and #2. This all could be 
because these antigens are too small (~2 kDa) to elicit an immune response alone 
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since SAPN was not providing additional antigenicity in our experiments. However, 
cannot reach a definite conclusion based on our data. 
 Additional to the data shown above, live images were obtained using an IVIS 
Series Pre-clinical In Vivo Imaging System (PerkinElmer) at approximately 19 hours, 
38 hours, 8 days and 15 days post-challenge in attempts to detect mCherry signal 
during liver stages. This information would help to assess if these immunizations 
were targeting the sporozoites before they reached the liver or if the infection was 
stopped right after the hepatic stage and prior establishing in the blood. 
Unfortunately, this study was inconclusive due to the high levels of mouse hair 
autofluorescence that resulted in high background signal and, probably, because of 
the hepatic stages were not severe enough to emit a detectable mCherry. 
 Other data not considered in this study was the multiple invasion events that 
were observed but not quantified due to the negative results of immunizations. This 
analysis should be included in future experiments. 
 Overall, we collected important information on other observations that 
should be taken into consideration in other experiments of this nature. It is possible 
that sometimes, important misleading information is inadvertently included in data 
analysis leading to wrongful conclusions. In our case, we documented information 
that is not often collected in this study for an in-depth analysis of the data. By 
recording the inoculation step of the experiment we were able to exclude data from 
one mouse that was not bitten by mosquitoes (Table 3.1), thus was never infected 
and could not be used in the parasitemia analysis. In later studies, by improving 
light conditions of recording, it will also be possible to quantify how many times 
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each mouse gets bitten by a mosquito or, at least, how many mosquitoes fed on each 
mouse. This information could help in data interpretation.  
 In conclusion, it was not possible to determine if SAPN is the best tool of 
antigen delivery for SUB2-targeted immunization. Nevertheless, we were able to 
show that antibodies that recognize recombinant SUB2 (Figure 2.2) can detect SAPN 
molecules harboring a combination of both SUB2 Peptide 1 and Peptide 2 or SAPN 
displaying Peptide 1 alone (Figure 3.8). This demonstrates that SUB2 peptides are 
displayed by SAPN in a way that can be recognized by the antibodies circulating in 
the blood. It does not proof, however, that SAPN-SUB2 alone can elicit an immune 
response for generating protective antibodies. Still, SAPN remains an attractive 
technology for future studies for optimization of SUB2 protection in mice. Follow-up 
















Figure 3.1 A SAPN-SUB2 fusion protein was developed for mice immunization. 
A) Structural model of coiled-coil SAPN-SUB2 subunit. The segment corresponding 
to the SUB2 peptide is shown in yellow. B) A structural model of the assembled 
SAPN displaying SUB2 peptides. Bottom: Table listing the three SAPNs utilized in 
these experiments. The SAPN only particle consisted of the SAPN protein without a 
SUB2 peptide sequence. SAPN-Peptide1 comprised of the SAPN protein with the 
SUB2 Peptide 1 sequence encoded in it for presenting to the target immune system. 
The last, SAPN-Peptide1+Peptide2 or “combination” is a mixed SAPN that includes 
both, a SAPN-Peptide1 protein and a SAPN-Peptide2 protein that were co-




Figure 3.2 Groups of mice employed in this experiment and their purpose. A 
total of 23 mice were used this immunization experiment that consisted of three 
groups of 6 mice that were immunized with the different SAPN antigens: SAPN-
Peptide1_Peptide2 (combination), SAPN-Peptide1, SAPN only (negative control). 
Two groups of mice that were not immunized were included in the experiment as 
additional controls. These consisted of one group of 6 naïve mice; these were 
challenged with P. berghei without being previously manipulated as a positive 
control of infection. The second group of non-immunized mice included only 3 mice 





Figure 3.3 P. berghei challenge by natural inoculation with mosquitoes. A) 
Microscopy image of A. stephensi mosquitoes approximately 24 hours prior to 
feeding. The mCherry signal coming from mosquitoes gut or salivary glands 
demonstrates the mosquitoes are prepared for transmission of the parasites to the 
mice during a blood meal. B) Experimental set up of the feeding experiment. C) A 
screenshot of the movie showing the experimental set up from the camera’s 
perspective from the bottom of the plastic plate prior placing the mice on top of the 
cups. D) Top view showing the array of the anesthetized mice placed on top of the 












Mouse # 1 2 3 4 5 6 
SAPN 
Control 9 6 9 9 7 10 
SAPN-
Combination 4 3 6 9 6 10 
SAPN-
Peptide1 9 1 0 5 7 6 
 
Table 3.1 Number of mosquitoes bites received by each mouse during natural 
inoculation via mosquito feeding. This table shows how many mosquitoes 
contained blood after the feeding experiment. The results were determined by 
observation of each individual mosquito collected after the feeding. It does not 
reflect how many times a mouse was bitten by mosquitoes but how many 
mosquitoes ingested blood from the mice. These data also do not distinguish 











Figure 3.4 Ring stage parasite found on SAPN-Peptide1 mouse #2 blood 
sample at day 3. A red blood cell with a ring stage parasite (black arrow) found on 
the blood smear of SAPN-Peptide1 mouse #2 at day 9 post-infection showing that 
this mouse resulted infected during a bite of one mosquito. Additional analyses are 









Figure 3.5 Parasitemia of SAPN immunized mice. A) Parasitemia from day 3 to 
day 10 post-infection. Blue shows data from SAPN control mice, purple corresponds 
to the data from SAPN-Peptide1 mice and orange indicates data from SAPN-
Peptide1+Peptide2 mice. Results show a similar trend between all groups of mice. 
SAPN-Peptide1 mice have an average of almost half the parasitemia compared to the 
control. B) Parasitemia of individual mice at day 10 post-infection, data points 
shown in blue, purple or orange. Mean values of each group are marked with a red 
bar; the standard deviation values are shown in black. C) Parasitemia up to day 19 




Figure 3.6 Plot of mouse survival. Survival of the mice was monitored over a 
period of 30 days post-infection. Data are shown in blue, purple and orange for 
SAPN control, SAPN-Peptide1 and SAPN-Peptide1+Peptide2 respectively. By day 24, 
all Peptide1+Peptide2 combination mice were dead. At day 30, the blood of two (33 
%) SAPN control mice that were still alive but very sick and two (33 %) SAPN-







Figure 3.7 Immunoblotting with recombinant PbSUB2 to confirm production 
of antibodies against PbSUB2. Top) A dot blot done using a 24-well culture plate 
to test production of anti-SUB2 antibodies by each individual mouse. The same 
construct MBP-fusion recombinant protein PbSUB2 tested previously in Chapter 2 
was used in this experiment. Results revealed that no anti-SUB2 antibodies were 
detected for the immunized mice. Mouse serum from KLH-SUB2 experiments 
(Figure 2.2) was used as a positive control. Bottom) An outline summarizing the 






Figure 3.8 Immunoblotting to confirm antibody production against the 
different SAPNs used for immunization. Top) A dot blot was done using a 24-well 
culture plate to test production of anti-SAPN, SAPN-Peptide1 or SAPN-
Peptide1+Peptide2 antibodies by each individual mouse. Antibody production was 
only confirmed for SAPN control mouse #4 and #5. There is a higher-than-
background signal for SAPN-Peptide1 mouse #2 and #3.  No other positive samples 
were detected. Although there was no signal using the SAPN control, there was a 
strong signal for SAPN-Peptide1 and SAPN-Peptide1+Peptide2 combination. SAPN-




















































 From the five species of Plasmodium parasites that infect humans, P. 
falciparum results in more severe malaria cases leading to deaths. Drug resistance of 
this species has been reported for all antimalarials currently available, including 
combination therapy in different malaria endemic regions. As a result, there both, 
effective vaccines and working drugs against malaria are urgently required for 
prevention and treatment of this potentially fatal infectious disease. 
 Calcium-dependent serine protease activity is essential for invasion of the 
host cell during the asexual developmental stages of the malaria parasite within the 
red blood cells (RBC). This activity leads to the shedding-off of merozoite surface 
ligands during invasion of the erythrocyte, catalyzed by subtilisin-like protease 2, 
the only Plasmodium subtilisin directly implicated in RBC invasion. Due to its critical 
role in parasite development during disease-causing blood stages, SUB2 represents 
a prime target for vaccine development and design of novel small molecule 
inhibitors of malaria infection. Yet, expression and purification of SUB2 have not 
been successfully achieved for in vitro biochemical and biophysical analyses. 
  To develop a Plasmodium SUB2-specific protease assay, we attempted to 
establish catalytically active recombinant protein expression and purification 
protocol. Various DNA constructs comprising the catalytic domain of PfSUB2 were 
developed and tested for protein expression in E. coli. These constructs include 
three different catalytically inactive variants were developed by mutating Ser and 
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His residues at the active site. Protease activity was initially tested using 
commercially available activity assays with general substrates.  
 Results demonstrate that many constructs including different domains of 
PfSUB2 can be expressed in E. coli.  Yet, recombinant PfSUB2 (rPfSUB2) is expressed 
insoluble in the absence of a solubility-adding tag, such as maltose-binding protein 
(MBP). MBP-SUB2 can be partially purified by affinity purification, but the yield and 
purity were not sufficient for biophysical analysis, such as protein crystallography. 
Additionally, it was not possible to conclusively show that rPfSUB2 was catalytically 
active using commercially available protease assays and in tests with general 
substrates. AMA1-derived substrates were developed for a SUB2-specific assay. 
Preliminary studies did yield positive results. 
 There were indications, however, that rPfSUB2 could have been active during 
expression in E. coli, such as slow cell growth and lysis. Yet, these observations could 
not be confirmed in these studies. Nonetheless, rPfSUB2 can be successfully 
employed in immunoblotting analyses, as discussed in Chapter 2 and 3. Follow-up 











 Obligate intracellular parasites have evolved to utilize protease activity for 
unique cellular mechanism leading to pathogenesis [129]. Host cell invasion is key 
for the survival of these unicellular organisms and the completion of their life cycle 
within their hosts, resulting in infectious disease symptoms [129]. Plasmodium, the 
causative agent of malaria, requires merozoite surface sheddase activity (MeSh) 
[45] for a successful invasion of the host cell during their asexual cycle within the 
vertebrate host.  
 Inhibition of shedding off the antigens at the merozoite surface may prevent 
or impair invasion [45], resulting in unsuccessful entry of the parasite into the 
erythrocyte. By preventing access of an obligate intracellular eukaryote to its target 
host cell, will have repercussions in the establishment of infection and its capacity to 
evade the host’s immune system. A decreasing number of parasites in the blood 
could potentially lead to the complete clearing of the infection. 
 MeSh activity has been attributed to the only Plasmodium subtilisin with a 
sheddase role during invasion: subtilisin-like protease 2 (SUB2)[45]. SUB2 (Figure 
4.1) is one of the three Plasmodium subtilisins encoded in the malaria parasite 
genome. It performs an essential and non-redundant role during red blood cell 
invasion that results in the merozoite surface sheddase activity that was reported 
before the identification of this second Plasmodium subtilisin. To this date, there is 
substantial understanding of the role of SUB2 upon invasion of the erythrocytes 
during the asexual stages of the parasite [40, 45, 96, 97, 99, 123] .  
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 However, the absence of a heterologous expression system for in vitro 
studies makes it impossible to develop a SUB2-specific protease assay. Biochemical 
and biophysical characterization of SUB2 is necessary for the better understanding 
of the mechanism of action of this subtilisin. These studies will also make possible to 
use a rational design approach to the development of small-molecule inhibitors or 
erythrocyte invasion by targeting SUB2.  
 To establish an expression and purification protocol for P. falciparum SUB2 
expression in E. coli, we have designed various expression constructs. These include 
constructs with different domains of SUB2, different fusion tags and AMA1-derived 
[96] substrates for a SUB2-specific activity assay. Protease assays with general 
substrates casein and gelatin were used to test SUB2 activity. However, it is not 
clear if SUB2 is expressed catalytically active in E. coli under the conditions tested. 
 
 
Methods and Materials 
 
Plasmodium cDNA  
 P. berghei ANKA and P. falciparum 3D7 isolation of total RNA and production 
of cDNA were performed as described in Chapter 2. 
 
PfSUB2 and PbSUB2 homology model and visualization for construct design 
 The predicted structure of PbSUB2 was obtained using the Iterative 
Threading ASSEmbly Refinement (I-TASSER) server as described in Chapter 2. 
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PfSUB2 predicted structure (Figure 4.2) was determined in the same manner but 
using PfSUB2 sequence (PDB PF3D7_1136900, Gene ID: 3423789). 
 
Primary PfSUB2 and PbSUB2 constructs 
 A primary construct for P. falciparum SUB2 N528 - S1135 (PlasmoDB code: 
PF3D7_1136900, Gene ID: 810927) and P. berghei  SUB2 N476 - N1185 (PlasmoDB 
code: PBANKA_091170, Gene ID: 3423789)  SUB2 were developed for storage of 
SUB2 sequence into a cloning vector for subcloning of SUB2 into various constructs 
for diverse purification and detection purposes. PfSUB2 or PbSUB2 coding 
sequences were amplified from cDNA obtained from P. falciparum 3D7 or P. berghei 
ANKA strains using Phusion® High-Fidelity DNA polymerase (New England 
Biolabs) and PCR program specifications described in Chapter 2.  
 Using NcoI and XhoI restriction sites, the PCR product was inserted in frame 
into a pHAT-5 vector (Bailey lab, BMB). Screening of positive clones was performed 
with the primers mentioned above using colony PCR followed by sequencing 
confirmation. 
 
Secondary PfSUB2 constructs 
 Secondary PfSUB2 constructs are those subcloned from the primary 
construct (Figure 4.3). SUB2 PCR products were inserted in-frame using NcoI and 
BamHI restriction sites into a modified pRSF-1b vector (Novagen). This vector 
allows the expression of a Maltose Binding Protein (MBP)-fusion protein with an 
additional C-terminal 6xHis tag added in the primer sequence. These tags were used 
 85 
for purification and detection purposes as described in Chapter 2. Positive clones 
were screened by colony PCR and insertion of the sequences was confirmed by 
sequencing. This protocol is similar to the one described in Chapter 2. 
 
PfSUB2 active site mutants 
 Catalytically inactive mutants H797G, S960A and H797G-S960A (Figure 4.4) 
of PfSUB2 were generated using a Site-Directed Mutagenesis Kit (Agilent 
Technologies) following the specifications of the instruction manual. Mutations 
were confirmed by sequencing. 
  
AMA1-derived substrates 
 Native apical membrane antigen 1 (AMA1) sequences cleaved by SUB2 as 
described in [100], were each cloned into a GKAR 1.2 vector (Jin Zhang Lab, JHU) 
using the restriction sites for SphI (5’) and BglII (3’). This allowed cloning of the 
different sequences between the yellow fluorescent protein (YFP) and blue 
fluorescent protein (CFP) on the vector (FIGURE 4.7A).  
 Primers where designed with overhangs ends simulating the cleavage of 
restriction enzymes, annealed and ligate into the expression vector. DNA oligos 
pairs ordered from Integrated DNA Technologies (IDT), Juxtamembrane_site-
Forward: cggCGCGCAGAAGTTACGAGCAACAATGAAGTCa and Juxtamembrane_site-
Reverse: agatctGACTTCATTGTTGCTCGTAACTTCTGCGCGccgcatgc, Poly_Alanine-
Forward: cggaggGCTGCCGCAGCGGCTGCCGCAgaagtta and Poly_Alanine-Reverse: 
agatctaacttcTGCGGCAGCCGCTGCGGCAGCcctccgcatgc, Proline_Rich-Forward: 
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cggCCGGCACCCGTACCCCCGAACCCGGAACCTa and Proline_Rich-Reverse: 
agatctAGGTTCCGGGTTCGGGGGTACGGGTGCCGGccgcatgc, and Intramembrane_Site-
Forward: cggAAAATCATTATCGCATCTAGTGCGGCAGTCa and Intramembrane_Site-
R: agatctGACTGCCGCACTAGATGCGATAATGATTTTccgcatgc, were annealed 
following protocol on the IDT website. Each primer pair was combined in a 1:1 
molar ratio by mixing 50 μl of 100 μM of the forward primer and 50 μl of 100 μM of 
the reverse primer with 100 μl of 2X annealing buffer (200 mM potassium acetate, 
60 mM HEPES pH 7.5). The mix was incubated for 5 minutes at 94 °C on a heat 
block. Then, the heat block was turned off and samples were allowed to cool down 
for about 45 minutes when the temperature of the samples dropped close to room 
temperature. Primers were stored at – 20 °C until ligated into the GKAR 1.2 vector. 
Screening was performed to confirm insertion of the different linkers by restriction 
enzyme digestion and analyzed by agarose gel electrophoresis. Finally, positive 
clones were confirmed by DNA sequencing. 
 
Expression of recombinant protein 
 Protein expression of SUB2 constructs was generally done as described in 
Chapter 2. RosettaTM 2 competent cells (Novagen) were transformed with 
expression vectors and grown overnight at 37 °C in a 50 ml starter culture. Protein 
was expressed in 500 ml cultures of Terrific Broth (TB). However, modifications 




Purification of recombinant protein 
 MBP-SUB2 constructs were purified as described in Chapter 2. Some 
modifications apply to some other constructs containing different tags for affinity 
purification (Figure 4.6).  
 
Zymogram gels 
 Protease activity of rSUB2 was tested using Ready Gel® zymogram precast 
gels (Bio-Rad) with casein or gelatin and with SDS-PAGE gels made in lab using Bio-
Rad manual with 0.1 % gelatin or 0.1 % casein. For electrophoresis, refolding and 
developing steps, the user’s instructions manual from Bio-Rad was followed. 
Developing step was usually performed overnight at 37 °C for optimal results. 
 
PfSUB2 protease assay with AMA1-derived substrates 
 A preliminary protease assay test with PfAMA-1 derived PfSUB2 substrates 
was performed by incubation of wild type and S960A PfSUB2 inactive mutant. 
Reactions were carried out in a protease assay buffer (25 mM HEPES pH 8.25, 150 
mM NaCl and 5 mM CaCl2) at 37 °C overnight. Results were analyzed by SDS-PAGE 
electrophoresis and coomassie brilliant blue stain. Some of the reactions included 
TEV protease for removal of MBP tag during the reaction. Two positive controls of 








 The activity rSUB2 was tested with in-gel casein and gelatin general 
substrates by zymography (Figure 4.7), both precast and lab made gels. With these 
assays there was no PfSUB2 activity detected but the trypsin control was positive. 
 
Protease assay test with GKAR AMA1-derived fluorescent substrates 
 Cleavage of fluorescent substrate with the poly alanine linker (Poly A) for the 
PfSUB2-specific protease assay was tested and analyzed by SDS-PAGE (Figure 8). 
Wild type PfSUB2 activity was compared to S960A PfSUB2 in the presence or 
absence of TEV protease. Under none of these conditions was there cleavage of the 
Poly A substrate by PfSUB2. On the other hand, positive controls trypsin and a 
bacterial subtilisin digested the full ~ 50 kDa Poly A substrate to a ~27 kDa and a 25 
kDa band respectively. TEV did not show activity against the Poly A substrate but it 
did cleave the MBP tag from the full-length recombinant SUB2. Results show the 
substrate is cleavage by trypsin and by a subtilisin. Thus, rSUB2 is not active under 









 Due to its critical role in red blood cell (RBC) invasion and because it is 
essential for Plasmodium survival during asexual stages, subtilisin-like protease 2 
(SUB2) is an attractive target for inhibition of parasite development during blood 
stages. Current malaria treatment is not based on SUB2 or other Plasmodium 
subtilisins. Biochemical and biophysical characterization of this molecular target 
will establish the basis of SUB2-targeted small-molecule inhibitors of RBC invasion.  
 Screening and development of small molecule inhibitors require expression 
and purification of the target protein of in vitro and biophysical studies. At the 
present, though, there are no reports of an effective expression and purification 
protocol for catalytically active recombinant Plasmodium SUB2. It is our purpose to 
establish an expression and purification protocol using E. coli as a heterologous 
expression system by developing various expression constructs using a structural 
model of SUB2. We have also attempted to develop a SUB-specific protease assay 
using native PfSUB2 substrates previously characterized in parasite cultures. 
 From our data we concluded that it is unclear if Plasmodium SUB2 is 
expressed actively in E. coli.  There are indications of protein toxicity while using E. 
coli as an expression system, that suggest SUB2 was expressed active in several 
occasions. However, we do not have conclusive data that will support these 
observations. Sequencing of the expression constructs isolated from E. coli cultures 
in which SUB2 was already expressed could reveal mutations in the SUB2 sequence 
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that might render the protein inactive leading to evidence that the activity of this 
protease is detrimental to the host. 
  Various SUB2 constructs can be expressed in E. coli using standard 
expression conditions; still SUB2 constructs containing the catalytic domain are 
insoluble unless expressed fused to MBP. This is not the case for the minimal 
domain of SUB2 that is highly soluble and can be expressed in high amounts with 
only a hexahistidine tag. Insolubility of the protein can indicate it is not correctly 
folded in E. coli or that it requires other buffer conditions or cofactors to aid in 
solubility. It is also possible that other truncations would lead to more stable and 
soluble protein since not all the possibilities were tested. Even if SUB2 will remain 
in the insoluble fraction upon cell lysis after successful expression, a preliminary 
circular dichroism (CD) experiment showed a signal for secondary structures 
additional to those found in MBP alone, when an MBP-SUB2 construct was tested. 
This specific CD experiment suggested that the catalytic domain of SUB2 was folded, 
at least partially, after being expressed in E. coli.  
  With the small amounts of soluble SUB2 we attempted several experiments 
such as protein crystallization and surface plasmon resonance that were not 
successfully carried out. Some crystals were obtained during primary screens with 
SUB2 protein but there were proved to be salt or they were non-diffracting.  
 Recombinant SUB2 was mostly useful for immunoblotting as confirmation of 
antibody generation with excellent results (Figure 2.2). This proves that constructs 
were well designed and the protein was expressed successfully. We have yet to find 
the best conditions for testing SUB2 activity. Additionally, trying out other 
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eukaryotic expression systems might yield better results. It is possible that SUB2 
requires more sophisticated cellular machinery for protein expression that can 
provide additional processing and post-translational modifications. 
 Testing of additional assay conditions should include Plasmodium growth 
media or blood sera to supplement for reaction components that might be missing 
for the buffers used in the lab. Since SUB2 is active when exposed to the 
extracellular environment during invasion, these tests should definitely show if the 
construct tested is active. In addition, SUB2 purified from the parasite might be a 
way to go for an in vitro assay until a recombinant version expressed in another 
system is proved to be active. 
 It is not trivial to accomplish in vitro studies of SUB2, however, it is important 
to pursue its biochemical characterization. In vitro studies will also contribute to the 
understanding of the mechanism of function of SUB2 at the biochemical level. In 
complement, biophysical characterization of its molecular structure will allow 
further characterization and set the basis for the development of SUB2-specific 
inhibitors. These approaches will facilitate the analysis of this subtilisin on an 
environment isolated from the cell, allowing the use of active site mutants. This 









Figure 4.1 Schematic of full length SUB2 compared to the minimal prodomain 
of SUB2 attached to the catalytic domain. Top) Domains found in full length 
SUB2: a signal peptide (black), prodomain (green) catalytic domain (red) with 
activity site residues (Asp, His and Ser), juxtamembrane domain (cyan), 
transmembrane domain (puple) and cytoplasmic tail (orange). Bottom) minimal 
prodomain (dark green) and catalytic domain (red). This minimal prodomain was 
included in some of the construct to aid in protein folding and stability. The 
juxtamembrane domain of SUB2 was unintentionally present in some of the 
constructs as a result of excluding the transmembrane domain while maintaining all 
the conserved regions adjacent to the catalytic domain. This figure was made using 











Figure 4.2 A predicted model of SUB2 was utilized as guidance in construct 
design. A structural model of PfSUB2 was generated using the I-TASSER server. A) 
Cartoon representation of PfSUB2 catalytic domain. The catalytic triad Asp, Ser and 
His is shown (sticks). B) PfSUB2 model aligned to PfSUB1 structure (4lvo) showing a 
fair alignment of the main secondary structures around the catalytic triad, yet, 
secondary structures distant from the active site are not accurately modeled but 








Figure 4.3 Example of P. falciparum and P. berghei SUB2 expression 
constructs. This figure shows several SUB2 constructs that were developed for 
biochemical and biophysical studies. Not all SUB2 constructs that were developed 
are included in this figure. Here, the prodomain (orange) is referred to the minimal 
prodomain that is included in these constructs for protein folding and stability 
purposes. The catalytic domain (purple) also includes the juxtamembrane region, 
which is also conserved. Maltose binding protein (MBP) was used to enhance 






Figure 4.4 Active site mutants of SUB2 were developed for a SUB2-specific 
protease assay.  Top) Left, active site residues (green, sticks representation) of 
wild type PfSUB2. Right, a schematic of the MBP-fusion construct used for 
developing the mutants by site-directed mutagenesis. Bottom) active site mutants: 
S960A inactive mutant, H797G mutant that can be activated by addition of imidazole 
(chemical-rescue mutant) and H797G, S960A double mutant as a negative control. 
Mutation is labeled with red fonts. These images were created using a homology 











Figure 4.5 Expression of PfSUB2 mutants and wild type. All SUB2 mutants and 
wild type were expressed in E. coli. Uninduced (U) and induced (I) whole cell 
samples were analyzed by SDS-PAGE stained with coomassie brilliant blue. Full 
length recombinant PfSUB2 can effectively be expressed in E. coli with the 










      
 
Figure 4.6 Recombinant protein stays soluble after removal of the MBP tag. 
Purified recombinant SUB2 was incubated with TEV protease to cleave off the MBP 
tag. Wild type and mutants of SUB2 were tested. Arrows show full length 
recombinant protein (top) and soluble PfSUB2 released from MBP after cleavage 
(bottom). All SUB2 mutants behaved the same as wild type in this assay. No 
evidence of autoproteolytic activity or degradation is observed. 50 kDa and 40 kDa 
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Figure 4.7 Protease activity of recombinant protein was tested by 
zymography. A) Experimental design and expected results in the presence or 
absence of imidazole, assuming that PfSUB2 is active when expressed in E. coli. 
Bottom: Results of zymogram assessment of PfSUB2 show no activity from this 
recombinant Plasmodium protease. The only activity observed in this assay is that 
from trypsin positive control. 






Figure 4.8 AMA1-based PfSUB2-specific substrates. A) GKAR substrate with 
AMA1 sites of SUB2 cleavage (Juxta site and Intra site) sequences and other 
sequences as positive (Poly Alanine) and negative (Proline rich) controls. B) Test of 
SUB2 activity with the Poly Alanine substrate. Trypsin and a bacterial subtilisin 
were included as positive controls. This Poly Alanine substrate is cleavable by 
proteases as demonstrated by the two stable products (~ 25 kDa) left by both, 
trypsin and the subtilisin control. However, no reaction products were observed for 
wild type SUB2 in the presence or absence of TEV protease that was included to 
remove the MBP tag. TEV cleavage of the full length SUB2 can be observed. In 
conclusion, SUB2 expressed in E. coli is not active under the conditions tested but 





























Plasmodium subtilisin-like protease 2 is a viable target for antibody-mediated 
inhibition of erythrocyte invasion 
 
 Out results show that, as predicted, immunization against SUB2 leads to a 
reduction of malaria infection in a mouse model of malaria, compared to control 
(Chapter 2). This shows that the short window in which the parasite is exposed to 
the blood is sufficient for the antibodies to interact with surface-exposed SUB2 and 
interfere with parasite invasion. Previous to this study, there was evidence that 
SUB2 antibodies were present in the blood of children in malaria endemic regions. 
The presence of antibodies in the blood was strongly correlated to protection from 
symptomatic malaria [130]. This evidence proves that SUB2 works as a merozoite 
surface antigen in addition to working as a merozoite surface sheddase. 
 A modified SAPN immunization protocol (Chapter 3) should be effective for 
antibody generation leading to protection against malaria in mice, as seen in 
previous experiments with KLH-conjugated SUB2 peptides (Chapter 2). Moreover, 
further optimization efforts will provide information on the requirements of SUB2-
mediated inhibition with antibodies. It will also be informative to test these 
antibodies in live parasite cultures and in biochemical assays. These can be used to 
explore if antibody-mediated inhibition also interferes with SUB2 protease activity, 
helping us to understand the mechanism on how these anti-SUB2 antibodies led to a 
decrease in parasite infection in mice. In addition, SAPN-SUB2 studies can also 
provide insights into how this approach will work with other molecular targets. 
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Current immunization protocol requires optimization for effective antibody-
mediated inhibition of asexual development of Plasmodium 
 
 Here, we have provided evidence of the potential of a SUB2-based vaccine for 
malaria. According to our results, with the correct protocol, it is possible to induce 
production of SUB2-specific antibodies in mice (Chapter 2). Furthermore, the 
presence of antibodies provides measurable protection from blood stages of the 
malaria parasite and potentially results in clearance, as observed in Chapter 2 
experiments. Since better results were achieved with the use of adjuvants and a KLH 
immunogenic carrier protein, it is possible that both or one of these components is 
required for induction of SUB2-targeted protection using SAPN as a delivery 
mechanism.  
 In our experiments, SAPN was solely used as an antigen-delivery tool 
(Chapter 3), with no additional elements for aiding to elicit an immune response. 
However, in some of the mice, a detectable amount of antibodies against the SAPN 
used for immunization was detected with immunoblotting. This shows that, even 
under non-optimal conditions, positive results can be achieved with this approach.  






Now, how to express and purify catalytically active Plasmodium SUB2 for in 
vitro studies? 
 
 Only a few studies focused on SUB2 have been published during the past 10 
years. This Plasmodium subtilisin is considered a major target for the design of 
antimalarials and, more recently, for vaccine development. It seems that, however, 
biochemical and biophysical studies have been impossible to perform in vitro 
because of the nonexistence of an appropriate expression system for active 
protease. It is unclear why SUB2 is not expressed in an active form in E. coli 
(Chapter 4). Though, it is not trivial to express active eukaryotic proteases in this 
expression system due to several factors including: post-translational modifications, 
incorrect formation of disulfide bonds, cytoplasmic protein concentration, protein 
solubility, among others. 
 It is also possible that SUB2 is expressed active in bacteria but critical 
components for SUB2 activity are missing from in vitro assay conditions that were 
tested. Future biochemical analyses should include activity assays with blood serum 
or parasite media to reach that conclusion, if true. Most likely, however, it will be 
necessary to express SUB2 using a eukaryotic heterologous expression system such 
as insect or human cells.  
 There are also other plausible options for obtaining catalytically active SUB2. 
For instance, a modified SUB2 with an extra protease cleavage site, could be 
introduced in the Plasmodium genome for expression in the parasite, to release 
SUB2 from the surface of the parasite upon secretion. Alternatively, a SUB2 
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construct could be developed for episomal expression to avoid detrimental effects of 
modifying all SUB2 in the parasite. Another option would be to express a SUB2 with 
a truncated C-terminal to exclude the transmembrane domain and secrete SUB2 
unattached from the parasite membrane. These are only a few options for 
expression of active SUB2 for in vitro studies that will also require additional 
modifications for purification purposes. To this date, it is unclear how we can 
express and purify active SUB2 for biochemical and biophysical characterization. 
 
 
SUB2 stands as a target for small-molecule and antibody-mediated inhibitor 
design against red blood cell stages of the malaria parasite 
 
 The role of SUB2 is essential for parasite survival and for RBC invasion, a 
critical step for Plasmodium asexual development [96, 131]. Blocking of parasite 
entry to the RBC results in parasite death, since it is an obligate intracellular 
parasite that requires a host cell for survival. In this case, a RBC confers protection 
from the host’s antibodies that are circulating in the blood and provides hemoglobin 
as a food source during asexual development. Precluding RBC invasion, therefore, 
means a fatal end for parasite. Thus, these results could be achieved by targeting 
SUB2. 
 In this dissertation, it was demonstrated that immunization with SUB2 
peptides leads to protection from blood stage parasites. This does not necessary 
mean that the antibodies are directly interfering with SUB2 activity, but targeting of 
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SUB2 could be effective for both, small-molecule and antibody-mediated inhibition 
of RBC invasion. It is known that serine-protease inhibitors result in inhibition of 
invasion by targeting a calcium-dependent merozoite surface sheddase (MeSh) 
activity. Prior to these studies, SUB2 was attributed to be responsible for the MeSh 
activity, which is essential during RBC invasion. We are just left with the task of 
figuring out how to gather biochemical data on SUB2 for the development of small 
molecule probes against its activity.  
 In vitro analyses will help to test if antibody and small molecule-mediated 
inhibition, both target SUB2 protease activity or if they work by different 
mechanisms of SUB2-targeted inhibition of RBC invasion. It is possible that these 
would have different mechanisms of action and could be used in complement to 
enhance the efficacy of inhibition using this target. In this case, different 
combinations could be utilized for different clinical scenarios of malaria or for 
different affected populations, for example. Putting together our results and those 
from previous studies, we can conclude that SUB2 is a suitable target for both, small 
molecule and antibody-mediated inhibition of RBC invasion. 
  
 
Additional future directions and final remarks 
  
 This work provides insights into preliminary research on a novel malaria 
vaccine candidate that was previously described as an attractive target for novel 
antimalarials. The proof-of-principle experimental data in Chapter 2 shows that 
 106 
SUB2 is a practical target for antibody-mediated inhibition of RBC invasion and that 
it results in clearance of malaria infection, in some cases.  From these and previous 
results we can also deduct that targeting SUB2 for small-molecule inhibitor design 
will result in impaired RBC invasion, preventing successful parasite entry. 
 As mentioned above, future studies on antibody-mediated inhibition elicited 
by immunization with SUB2 peptides should take into consideration the addition of 
a suitable adjuvant, a carrier protein, additional boosts and verification of antibody 
generation prior to the challenge with P. berghei. The use of self-assembling protein 
nanoparticles (SAPN) should still be employed in future experiments since there are 
advantages in using a delivery system that can be developed in a laboratory by 
standard expression and purification protocols using E. coli expression system. This 
technology also permits us to combine different antigens and could be used to target 
several strains or species of the parasite for a more potent and effective vaccine. 
 In future studies, it should be considered to collect a variety of observations 
and data throughout the course of the experiment, as it was implemented in the 
SAPN studies (Chapter 3). For example, by recording the P. berghei challenge by 
mosquito feeding, we were able to determine that mosquitoes did not bite one of the 
mice. By knowing this, we did not include its data in the parasitemia analysis. 
Inclusion of this information would have affected the data in how the mice were 
protected and parasite clearance. Live imaging, if optimized, could provide 
information about when during the blood stages antibody-mediated inhibition is 
effective. It is possible that in some mice the parasites go thru liver stages but they 
never establish in the blood because the antibodies interfere with the initial 
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merozoites coming out of the liver, prior invading erythrocytes in the first place. 
 Also, multiple invasion events should be measured in follow-up studies as it 
could hint to details of the mechanism of antibody-mediated inhibition of parasite 
invasion of RBCs by the malaria parasite. To confirm the presence low levels of 
parasitemia, DNA sequencing of infected RBCs using P. berghei- specific primers 
may aid in detecting low levels of parasite infection that would not be measurable 
on the Image Stream due to signal-to-noise ratio. This will permit to detect early 
blood stage infection prior to elimination by antibody-mediated inhibition. 
However, additional blood samples would need to be collected. 
 In conclusion, our results provide proof that SUB2 is a suitable target for 
vaccine development and should still be considered a target for the development of 
new antimalarials. It is important to continue studies that promise to achieve better 
understanding of this molecular target. We yet have to establish a method for 
biochemical and biophysical characterization of SUB2. Here, we have provided the 
basis for vaccine development based on this target. Studies performed with this 
Plasmodium subtilisin could also provide the basics for developing treatment based 
on similar targets for other diseases. 
 Finally, Perhaps, the key for successful control of malaria relies in a specific 
complex combination of factors and not solely on a single “magic” drug or vaccine. 
The better understanding of the cellular mechanisms of malaria pathogenesis and 
the characterization of molecular targets, the more prepared we are to fight against 
this and other infectious diseases. 
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 This dissertation illustrates some of the multiple challenges that are faced in 
the attempts to develop treatment and protection against malaria infection. The 
more information we gather, the better prepared we are to continue fighting against 
this infectious disease caused by Plasmodium parasites. This antibody-mediated 
inhibitor design is a rational approach permitting to shape the advancement in the 
characterization of this targets and optimization of the use of the inhibitors. Only by 
acquiring all the necessary tools for malaria control, we will be moving towards the 
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